https://trial.medpath.com/news/immunotech-b-targets-39-month-timeline-for-eal-resubmission-in-liver-cancer-advances-atl-cell-therapy-commercialization 2026-06-04T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotech-b-targets-39-month-timeline-for-eal-resubmission-in-liver-cancer-advances-atl-cell-therapy-commercialization 2026-06-04T12:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-secures-asia-pacific-rights-to-bejescin-the-first-cd20-antibody-approved-for-nmosd 2026-06-04T12:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-secures-asia-pacific-rights-to-bejescin-the-first-cd20-antibody-approved-for-nmosd 2026-06-04T12:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-saves-stage-4-bowel-cancer-patient-a-decade-long-journey-from-terminal-diagnosis-to-cancer-free 2026-06-04T12:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-saves-stage-4-bowel-cancer-patient-a-decade-long-journey-from-terminal-diagnosis-to-cancer-free 2026-06-04T12:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/how-china-s-legend-biotech-and-llama-nanobodies-changed-the-course-of-multiple-myeloma 2026-06-04T12:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-china-s-legend-biotech-and-llama-nanobodies-changed-the-course-of-multiple-myeloma 2026-06-04T12:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/daltontx-launches-ai-powered-drug-discovery-platform-signs-sygnature-discovery-as-first-client 2026-06-04T11:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daltontx-launches-ai-powered-drug-discovery-platform-signs-sygnature-discovery-as-first-client 2026-06-04T11:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/tlr5-receptor-identified-as-key-protective-pathway-in-idiopathic-pulmonary-fibrosis-mouse-studies-show-therapeutic-promise 2026-06-04T11:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tlr5-receptor-identified-as-key-protective-pathway-in-idiopathic-pulmonary-fibrosis-mouse-studies-show-therapeutic-promise 2026-06-04T11:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/fosnetupitant-outperforms-fosaprepitant-in-long-delayed-cinv-control-for-folfirinox-folfoxiri-regimens 2026-06-04T11:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosnetupitant-outperforms-fosaprepitant-in-long-delayed-cinv-control-for-folfirinox-folfoxiri-regimens 2026-06-04T11:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/uk-regulator-updates-spc-for-senvelgo-oral-solution-in-cats-narrows-indication-and-strengthens-safety-warnings 2026-06-04T11:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-regulator-updates-spc-for-senvelgo-oral-solution-in-cats-narrows-indication-and-strengthens-safety-warnings 2026-06-04T11:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/3billion-to-present-on-rare-disease-genomic-diagnostics-and-reanalysis-at-two-european-conferences-in-june-2026 2026-06-04T11:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3billion-to-present-on-rare-disease-genomic-diagnostics-and-reanalysis-at-two-european-conferences-in-june-2026 2026-06-04T11:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development 2026-06-04T10:06:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development 2026-06-04T10:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/ocean-warming-patterns-help-predict-malaria-transmission-in-malawi-study-finds 2026-06-04T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocean-warming-patterns-help-predict-malaria-transmission-in-malawi-study-finds 2026-06-04T09:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-submits-accelerated-approval-application-for-povetacicept-in-iga-nephropathy-targets-november-decision 2026-06-04T09:06:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-submits-accelerated-approval-application-for-povetacicept-in-iga-nephropathy-targets-november-decision 2026-06-04T09:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-abbvie-s-elahere-for-platinum-resistant-ovarian-cancer-marking-first-new-nhs-option-in-over-20-years 2026-06-04T09:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-abbvie-s-elahere-for-platinum-resistant-ovarian-cancer-marking-first-new-nhs-option-in-over-20-years 2026-06-04T09:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-sector-wide-rally-lifts-exelixis-ptc-therapeutics-and-peers-as-investors-rotate-into-oncology-and-rare-disease-names 2026-06-04T09:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-sector-wide-rally-lifts-exelixis-ptc-therapeutics-and-peers-as-investors-rotate-into-oncology-and-rare-disease-names 2026-06-04T09:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/brain-navi-s-krystolens-single-use-neuro-endoscope-receives-tfda-certification-for-taiwan-market-entry 2026-06-04T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-navi-s-krystolens-single-use-neuro-endoscope-receives-tfda-certification-for-taiwan-market-entry 2026-06-04T09:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/stevanato-group-shareholders-approve-all-resolutions-at-2026-annual-meeting-including-dividend-and-board-appointments 2026-06-04T09:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stevanato-group-shareholders-approve-all-resolutions-at-2026-annual-meeting-including-dividend-and-board-appointments 2026-06-04T09:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-s-mhc-i-evasion-trick-backfires-cd4-t-cells-unleash-ferroptosis-against-tumors 2026-06-04T08:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-s-mhc-i-evasion-trick-backfires-cd4-t-cells-unleash-ferroptosis-against-tumors 2026-06-04T08:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-machine-learning-and-molecular-dynamics-framework-identifies-novel-gsk-3b-inhibitor-candidates-for-alzheimer-s-disease 2026-06-04T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-machine-learning-and-molecular-dynamics-framework-identifies-novel-gsk-3b-inhibitor-candidates-for-alzheimer-s-disease 2026-06-04T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/the-cancer-alzheimer-s-paradox-unraveling-the-inverse-relationship-between-two-age-related-diseases 2026-06-04T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-cancer-alzheimer-s-paradox-unraveling-the-inverse-relationship-between-two-age-related-diseases 2026-06-04T07:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/mounting-evidence-confirms-no-safe-level-of-alcohol-consumption-cancer-brain-damage-and-mortality-risks-highlighted 2026-06-04T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mounting-evidence-confirms-no-safe-level-of-alcohol-consumption-cancer-brain-damage-and-mortality-risks-highlighted 2026-06-04T07:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/seven-critical-challenges-to-curing-brain-tumours-a-call-to-arms-from-cancer-research-uk 2026-06-04T07:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seven-critical-challenges-to-curing-brain-tumours-a-call-to-arms-from-cancer-research-uk 2026-06-04T07:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-engineered-hookworms-produce-functional-antitoxin-in-animal-hosts-paving-way-for-living-drug-factories 2026-06-04T07:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-engineered-hookworms-produce-functional-antitoxin-in-animal-hosts-paving-way-for-living-drug-factories 2026-06-04T07:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-microenvironment-drives-differential-anti-angiogenic-response-in-lung-cancer-subtypes-study-finds 2026-06-04T07:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-microenvironment-drives-differential-anti-angiogenic-response-in-lung-cancer-subtypes-study-finds 2026-06-04T07:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-family-races-to-fund-personalized-gene-therapy-for-son-s-rare-neurodegenerative-disease 2026-06-04T07:06:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-family-races-to-fund-personalized-gene-therapy-for-son-s-rare-neurodegenerative-disease 2026-06-04T07:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/china-positions-rare-disease-sector-as-strategic-innovation-frontier-with-34-5-market-growth-projected 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-positions-rare-disease-sector-as-strategic-innovation-frontier-with-34-5-market-growth-projected 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-moves-to-reclassify-top-nih-officials-as-political-appointees-raising-concerns-over-research-independence 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-moves-to-reclassify-top-nih-officials-as-political-appointees-raising-concerns-over-research-independence 2026-06-04T06:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/tau-s-dual-role-essential-for-long-term-memory-formation-yet-disrupted-by-amyloid-beta-in-alzheimer-s 2026-06-04T05:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tau-s-dual-role-essential-for-long-term-memory-formation-yet-disrupted-by-amyloid-beta-in-alzheimer-s 2026-06-04T05:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-updated-cybersecurity-guidance-for-medical-device-premarket-submissions 2026-06-04T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-updated-cybersecurity-guidance-for-medical-device-premarket-submissions 2026-06-04T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/memory-b-cells-reveal-blueprint-for-nasal-vaccines-that-could-stop-respiratory-infections-at-their-entry-point 2026-06-04T04:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memory-b-cells-reveal-blueprint-for-nasal-vaccines-that-could-stop-respiratory-infections-at-their-entry-point 2026-06-04T04:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-adipose-tumor-axis-unraveling-how-fat-tissue-drives-cancer-progression-and-shapes-therapeutic-response 2026-06-04T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-adipose-tumor-axis-unraveling-how-fat-tissue-drives-cancer-progression-and-shapes-therapeutic-response 2026-06-04T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/microsoft-and-mayo-clinic-partner-to-build-healthcare-specific-ai-model-for-clinical-reasoning-and-patient-support 2026-06-04T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microsoft-and-mayo-clinic-partner-to-build-healthcare-specific-ai-model-for-clinical-reasoning-and-patient-support 2026-06-04T03:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/metformin-s-longevity-potential-new-research-links-atp5i-mitochondrial-protein-to-healthy-aging-benefits 2026-06-04T01:05:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metformin-s-longevity-potential-new-research-links-atp5i-mitochondrial-protein-to-healthy-aging-benefits 2026-06-04T01:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/medicaid-work-requirements-threaten-continuous-coverage-for-cancer-and-hiv-patients-advocates-warn 2026-06-04T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicaid-work-requirements-threaten-continuous-coverage-for-cancer-and-hiv-patients-advocates-warn 2026-06-04T01:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/amish-health-paradox-rapid-population-growth-distinct-disease-profiles-and-the-complex-realities-behind-vaccine-narratives 2026-06-04T00:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amish-health-paradox-rapid-population-growth-distinct-disease-profiles-and-the-complex-realities-behind-vaccine-narratives 2026-06-04T00:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-lotis-5-trial-meets-pfs-endpoint-but-safety-concerns-cloud-zynlonta-combination-in-dlbcl 2026-06-04T00:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-therapeutics-lotis-5-trial-meets-pfs-endpoint-but-safety-concerns-cloud-zynlonta-combination-in-dlbcl 2026-06-04T00:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-grants-marketing-authorisation-for-cinnagen-s-teriparatide-biosimilar-zandoriah-a-first-for-iranian-pharma 2026-06-04T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-grants-marketing-authorisation-for-cinnagen-s-teriparatide-biosimilar-zandoriah-a-first-for-iranian-pharma 2026-06-04T00:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/cocrystal-pharma-appoints-antiviral-drug-development-veteran-carol-brosgart-md-to-board-of-directors 2026-06-04T00:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cocrystal-pharma-appoints-antiviral-drug-development-veteran-carol-brosgart-md-to-board-of-directors 2026-06-04T00:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/ironwood-reports-97-linzess-sales-surge-advances-apraglutide-toward-stars-2-trial-initiation 2026-06-04T00:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ironwood-reports-97-linzess-sales-surge-advances-apraglutide-toward-stars-2-trial-initiation 2026-06-04T00:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-era-of-alzheimer-s-treatment-prevention-trials-combination-therapies-and-biomarker-driven-early-detection-converge 2026-06-04T00:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-next-era-of-alzheimer-s-treatment-prevention-trials-combination-therapies-and-biomarker-driven-early-detection-converge 2026-06-04T00:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/silence-therapeutics-reports-positive-phase-ii-zerlasiran-data-and-phase-i-divesiran-results-extends-cash-runway-into-2027 2026-06-04T00:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silence-therapeutics-reports-positive-phase-ii-zerlasiran-data-and-phase-i-divesiran-results-extends-cash-runway-into-2027 2026-06-04T00:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/montara-therapeutics-secures-1m-michael-j-fox-foundation-grant-to-advance-brain-selective-mtor-therapy-for-parkinson-s-disease 2026-06-04T00:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montara-therapeutics-secures-1m-michael-j-fox-foundation-grant-to-advance-brain-selective-mtor-therapy-for-parkinson-s-disease 2026-06-04T00:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/bundibugyo-ebola-outbreak-in-drc-declared-public-health-emergency-no-licensed-vaccine-over-1000-cases-in-100-days 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bundibugyo-ebola-outbreak-in-drc-declared-public-health-emergency-no-licensed-vaccine-over-1000-cases-in-100-days 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/soccer-heading-linked-to-acute-spikes-in-neural-damage-biomarkers-s100b-and-p-tau217-in-amateur-players 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soccer-heading-linked-to-acute-spikes-in-neural-damage-biomarkers-s100b-and-p-tau217-in-amateur-players 2026-06-04T00:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/trumprx-drug-discount-platform-expands-to-over-750-medications-cms-administrator-oz-announces 2026-06-04T00:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trumprx-drug-discount-platform-expands-to-over-750-medications-cms-administrator-oz-announces 2026-06-04T00:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/upc-milan-revokes-remdesivir-patent-for-lack-of-inventive-step-drawing-sharp-distinction-between-reasonable-expectation-and-mere-hope-of-success 2026-06-03T23:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-milan-revokes-remdesivir-patent-for-lack-of-inventive-step-drawing-sharp-distinction-between-reasonable-expectation-and-mere-hope-of-success 2026-06-03T23:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/apoha-emerges-from-stealth-with-36m-to-revolutionize-drug-development-through-molecular-behavior-analysis 2026-06-03T23:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apoha-emerges-from-stealth-with-36m-to-revolutionize-drug-development-through-molecular-behavior-analysis 2026-06-03T23:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/corrixr-therapeutics-names-seagen-veteran-nancy-whiting-as-board-chair-ahead-of-crispr-oncology-push 2026-06-03T23:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corrixr-therapeutics-names-seagen-veteran-nancy-whiting-as-board-chair-ahead-of-crispr-oncology-push 2026-06-03T23:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-advances-cancer-pipeline-with-two-phase-ii-trials-for-alisertib 2026-06-03T23:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-advances-cancer-pipeline-with-two-phase-ii-trials-for-alisertib 2026-06-03T23:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/biopharmaceutical-innovation-the-patent-imperative-under-siege 2026-06-03T23:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharmaceutical-innovation-the-patent-imperative-under-siege 2026-06-03T23:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-regains-nasdaq-compliance-after-minimum-bid-price-deficiency 2026-06-03T23:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotechnology-regains-nasdaq-compliance-after-minimum-bid-price-deficiency 2026-06-03T23:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/rousselot-secures-u-s-patent-for-nextida-gc-a-first-of-its-kind-collagen-peptide-for-post-meal-blood-glucose-support 2026-06-03T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rousselot-secures-u-s-patent-for-nextida-gc-a-first-of-its-kind-collagen-peptide-for-post-meal-blood-glucose-support 2026-06-03T23:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-enables-kidney-transplants-in-highly-sensitized-patients-in-first-of-its-kind-trial 2026-06-03T23:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-enables-kidney-transplants-in-highly-sensitized-patients-in-first-of-its-kind-trial 2026-06-03T23:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/even-safe-levels-of-air-pollution-linked-to-coronary-artery-disease-especially-in-women 2026-06-03T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/even-safe-levels-of-air-pollution-linked-to-coronary-artery-disease-especially-in-women 2026-06-03T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/multi-omics-and-ai-integration-reshapes-precision-drug-discovery-from-target-identification-to-clinical-translation 2026-06-03T22:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multi-omics-and-ai-integration-reshapes-precision-drug-discovery-from-target-identification-to-clinical-translation 2026-06-03T22:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-partners-with-ai-pioneer-inceptive-in-2b-collaboration-to-accelerate-rnai-drug-discovery 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-partners-with-ai-pioneer-inceptive-in-2b-collaboration-to-accelerate-rnai-drug-discovery 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/pune-scientists-develop-dual-gene-silencing-nanocarrier-for-targeted-breast-cancer-therapy 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pune-scientists-develop-dual-gene-silencing-nanocarrier-for-targeted-breast-cancer-therapy 2026-06-03T22:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-launches-section-301-investigation-into-german-drug-pricing-citing-unfair-cost-shifting-to-american-patients 2026-06-03T22:05:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-launches-section-301-investigation-into-german-drug-pricing-citing-unfair-cost-shifting-to-american-patients 2026-06-03T22:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-draft-guidance-on-drug-and-device-manufacturer-communications-with-payors-incorporating-pie-act-provisions 2026-06-03T22:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-draft-guidance-on-drug-and-device-manufacturer-communications-with-payors-incorporating-pie-act-provisions 2026-06-03T22:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-merck-pursue-divergent-strategies-as-pipeline-pressures-mount 2026-06-03T22:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-merck-pursue-divergent-strategies-as-pipeline-pressures-mount 2026-06-03T22:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/zepto-life-technology-receives-fda-breakthrough-device-designation-for-fungiflex-mold-panel-liquid-biopsy-test 2026-06-03T22:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zepto-life-technology-receives-fda-breakthrough-device-designation-for-fungiflex-mold-panel-liquid-biopsy-test 2026-06-03T22:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/3d-bioprinting-of-cartilage-tissue-on-the-iss-advances-regenerative-medicine 2026-06-03T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-bioprinting-of-cartilage-tissue-on-the-iss-advances-regenerative-medicine 2026-06-03T21:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/pila-pharma-receives-ema-go-ahead-to-start-obesity-trials-for-trpv1-antagonist-xen-d0501 2026-06-03T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pila-pharma-receives-ema-go-ahead-to-start-obesity-trials-for-trpv1-antagonist-xen-d0501 2026-06-03T21:07:21+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-profiling-and-advanced-imaging-guide-personalized-treatment-in-complex-secondary-meningioma-after-childhood-medulloblastoma 2026-06-03T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-profiling-and-advanced-imaging-guide-personalized-treatment-in-complex-secondary-meningioma-after-childhood-medulloblastoma 2026-06-03T21:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/asbmb-highlights-career-development-and-funding-opportunities-for-biomedical-researchers 2026-06-03T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asbmb-highlights-career-development-and-funding-opportunities-for-biomedical-researchers 2026-06-03T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-to-withdraw-low-dose-zoladex-from-australian-market-raising-concerns-for-breast-cancer-and-endometriosis-patients 2026-06-03T20:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-to-withdraw-low-dose-zoladex-from-australian-market-raising-concerns-for-breast-cancer-and-endometriosis-patients 2026-06-03T20:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/us-investigation-into-germany-s-drug-pricing-reignites-global-debate-on-pharmaceutical-innovation-costs 2026-06-03T20:07:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-investigation-into-germany-s-drug-pricing-reignites-global-debate-on-pharmaceutical-innovation-costs 2026-06-03T20:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-may-improve-testosterone-levels-and-sperm-quality-in-men-with-obesity-studies-suggest 2026-06-03T20:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-may-improve-testosterone-levels-and-sperm-quality-in-men-with-obesity-studies-suggest 2026-06-03T20:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/coral-inspired-3d-printed-scaffold-reprograms-immune-cells-to-repair-steroid-induced-bone-death 2026-06-03T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coral-inspired-3d-printed-scaffold-reprograms-immune-cells-to-repair-steroid-induced-bone-death 2026-06-03T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-biological-insights-into-progressive-multiple-sclerosis-multi-omics-study-identifies-six-key-proteins-with-therapeutic-potential 2026-06-03T19:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-biological-insights-into-progressive-multiple-sclerosis-multi-omics-study-identifies-six-key-proteins-with-therapeutic-potential 2026-06-03T19:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-map-reveals-how-genetic-variation-drives-inflammatory-bowel-disease-opening-new-paths-for-drug-development 2026-06-03T19:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-map-reveals-how-genetic-variation-drives-inflammatory-bowel-disease-opening-new-paths-for-drug-development 2026-06-03T19:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/ai-enabled-antibiotic-discovery-identifies-novel-compounds-against-drug-resistant-gonorrhea 2026-06-03T19:09:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-enabled-antibiotic-discovery-identifies-novel-compounds-against-drug-resistant-gonorrhea 2026-06-03T19:09:26+00:00 hourly 0.9 https://trial.medpath.com/news/schott-pharma-usa-triples-manufacturing-capacity-with-60-million-pennsylvania-expansion 2026-06-03T19:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schott-pharma-usa-triples-manufacturing-capacity-with-60-million-pennsylvania-expansion 2026-06-03T19:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/ketogenic-therapy-shows-promise-for-anorexia-nervosa-treatment-in-uc-san-diego-clinical-trial 2026-06-03T19:07:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ketogenic-therapy-shows-promise-for-anorexia-nervosa-treatment-in-uc-san-diego-clinical-trial 2026-06-03T19:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/house-judiciary-subcommittee-to-examine-drug-patent-protections-amid-tariff-and-pricing-tensions 2026-06-03T19:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/house-judiciary-subcommittee-to-examine-drug-patent-protections-amid-tariff-and-pricing-tensions 2026-06-03T19:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/nrf2-s-dual-role-in-ferroptosis-a-context-dependent-switch-for-cancer-therapy 2026-06-03T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nrf2-s-dual-role-in-ferroptosis-a-context-dependent-switch-for-cancer-therapy 2026-06-03T18:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/synthetic-human-genome-project-deserves-revival-with-a-new-minimalist-vision 2026-06-03T18:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthetic-human-genome-project-deserves-revival-with-a-new-minimalist-vision 2026-06-03T18:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/more-than-2000-beagles-released-from-wisconsin-research-facility-as-questions-mount-over-federal-oversight 2026-06-03T18:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/more-than-2000-beagles-released-from-wisconsin-research-facility-as-questions-mount-over-federal-oversight 2026-06-03T18:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-spatial-pharmacobiology-platform-reveals-stromal-barriers-to-antibody-delivery-in-human-solid-tumors 2026-06-03T18:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-spatial-pharmacobiology-platform-reveals-stromal-barriers-to-antibody-delivery-in-human-solid-tumors 2026-06-03T18:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/arb-based-antihypertensive-regimens-show-superior-tolerability-in-large-network-meta-analysis 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arb-based-antihypertensive-regimens-show-superior-tolerability-in-large-network-meta-analysis 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/jjp-biologics-reports-positive-phase-1b-data-for-first-in-class-anti-cd89-antagonist-in-rare-autoimmune-disease 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jjp-biologics-reports-positive-phase-1b-data-for-first-in-class-anti-cd89-antagonist-in-rare-autoimmune-disease 2026-06-03T18:06:41+00:00 hourly 0.9 https://trial.medpath.com/news/top-ultra-processed-food-researchers-call-for-sweeping-policy-changes-citing-broad-public-support 2026-06-03T18:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/top-ultra-processed-food-researchers-call-for-sweeping-policy-changes-citing-broad-public-support 2026-06-03T18:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-ai-based-digital-liver-model-into-istand-program-to-predict-drug-induced-liver-injury 2026-06-03T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-ai-based-digital-liver-model-into-istand-program-to-predict-drug-induced-liver-injury 2026-06-03T18:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/senior-nih-scientists-charged-with-smuggling-deactivated-mpox-virus-into-u-s-sparking-congressional-investigation 2026-06-03T18:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senior-nih-scientists-charged-with-smuggling-deactivated-mpox-virus-into-u-s-sparking-congressional-investigation 2026-06-03T18:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/analyst-ratings-diverge-on-healthcare-stocks-as-moderna-faces-continued-pressure 2026-06-03T18:06:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analyst-ratings-diverge-on-healthcare-stocks-as-moderna-faces-continued-pressure 2026-06-03T18:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/north-america-dna-sequencing-market-to-reach-27-56-billion-by-2035-driven-by-precision-medicine-and-oncology-applications 2026-06-03T18:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/north-america-dna-sequencing-market-to-reach-27-56-billion-by-2035-driven-by-precision-medicine-and-oncology-applications 2026-06-03T18:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-prices-eur950-million-senior-notes-offering-to-refinance-debt-and-strengthen-financial-flexibility 2026-06-03T18:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-prices-eur950-million-senior-notes-offering-to-refinance-debt-and-strengthen-financial-flexibility 2026-06-03T18:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/collate-raises-95-million-series-a-to-bring-ai-native-automation-to-regulated-life-sciences-workflows 2026-06-03T18:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collate-raises-95-million-series-a-to-bring-ai-native-automation-to-regulated-life-sciences-workflows 2026-06-03T18:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-technologies-aim-to-overcome-immunotherapy-barriers-in-brain-cancers 2026-06-03T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerging-technologies-aim-to-overcome-immunotherapy-barriers-in-brain-cancers 2026-06-03T18:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-shares-plummet-37-following-phase-3-obefazimod-safety-concerns-in-ulcerative-colitis 2026-06-03T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-shares-plummet-37-following-phase-3-obefazimod-safety-concerns-in-ulcerative-colitis 2026-06-03T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/neuralight-s-eye-tracking-biomarker-outperforms-mds-updrs-iii-in-detecting-parkinson-s-disease-progression 2026-06-03T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuralight-s-eye-tracking-biomarker-outperforms-mds-updrs-iii-in-detecting-parkinson-s-disease-progression 2026-06-03T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-proposes-sweeping-rule-change-to-politicize-federal-science-funding 2026-06-03T16:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-proposes-sweeping-rule-change-to-politicize-federal-science-funding 2026-06-03T16:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/fenebrutinib-shows-efficacy-in-both-relapsing-and-progressive-ms-but-safety-signals-raise-questions 2026-06-03T16:12:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fenebrutinib-shows-efficacy-in-both-relapsing-and-progressive-ms-but-safety-signals-raise-questions 2026-06-03T16:12:54+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference-and-report-q2-2026-financial-results 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference-and-report-q2-2026-financial-results 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-ceo-reports-50-faster-drug-candidate-selection-through-ai-implementation 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-ceo-reports-50-faster-drug-candidate-selection-through-ai-implementation 2026-06-03T16:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-ascidian-therapeutics-in-1-9-billion-rna-exon-editing-deal-for-kidney-diseases 2026-06-03T16:12:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-partners-with-ascidian-therapeutics-in-1-9-billion-rna-exon-editing-deal-for-kidney-diseases 2026-06-03T16:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-transplantation-most-cost-effective-curative-option-for-sickle-cell-disease-study-finds 2026-06-03T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-transplantation-most-cost-effective-curative-option-for-sickle-cell-disease-study-finds 2026-06-03T16:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/cheme-show-2026-highlights-convergence-of-pharmaceutical-and-petrochemical-manufacturing-technologies 2026-06-03T16:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cheme-show-2026-highlights-convergence-of-pharmaceutical-and-petrochemical-manufacturing-technologies 2026-06-03T16:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/idefine-partners-with-ut-southwestern-to-develop-first-gene-therapy-for-kleefstra-syndrome 2026-06-03T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idefine-partners-with-ut-southwestern-to-develop-first-gene-therapy-for-kleefstra-syndrome 2026-06-03T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/vanderbilt-researchers-discover-first-selective-taok1-inhibitor-and-unexpected-pan-taok-activator-opening-new-avenues-for-alzheimer-s-research 2026-06-03T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vanderbilt-researchers-discover-first-selective-taok1-inhibitor-and-unexpected-pan-taok-activator-opening-new-avenues-for-alzheimer-s-research 2026-06-03T16:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/tearsolutions-receives-fda-orphan-drug-and-fast-track-designations-for-lacripep-in-neurotrophic-keratitis-initiates-phase-2-trial 2026-06-03T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tearsolutions-receives-fda-orphan-drug-and-fast-track-designations-for-lacripep-in-neurotrophic-keratitis-initiates-phase-2-trial 2026-06-03T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-significant-infection-risks-linked-to-antibody-drug-conjugates-in-cancer-patients 2026-06-03T16:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-significant-infection-risks-linked-to-antibody-drug-conjugates-in-cancer-patients 2026-06-03T16:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-vertex-s-biologics-license-application-for-povetacicept-in-iga-nephropathy-setting-november-2026-decision-date 2026-06-03T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-vertex-s-biologics-license-application-for-povetacicept-in-iga-nephropathy-setting-november-2026-decision-date 2026-06-03T16:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/cross-linking-mass-spectrometry-reveals-how-influenza-a-virus-rewires-host-cells-at-unprecedented-structural-resolution 2026-06-03T16:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cross-linking-mass-spectrometry-reveals-how-influenza-a-virus-rewires-host-cells-at-unprecedented-structural-resolution 2026-06-03T16:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/american-heart-association-launches-first-ever-national-heart-transplant-research-network-to-transform-patient-care 2026-06-03T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/american-heart-association-launches-first-ever-national-heart-transplant-research-network-to-transform-patient-care 2026-06-03T16:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-and-manchester-secure-major-uk-funding-for-ai-driven-personalised-cancer-vaccines-and-immunotherapy-research 2026-06-03T16:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-and-manchester-secure-major-uk-funding-for-ai-driven-personalised-cancer-vaccines-and-immunotherapy-research 2026-06-03T16:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/hkeybio-launches-comprehensive-autoimmune-disease-model-platform-for-drug-development 2026-06-03T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hkeybio-launches-comprehensive-autoimmune-disease-model-platform-for-drug-development 2026-06-03T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial-stony-brook-researchers-report 2026-06-03T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial-stony-brook-researchers-report 2026-06-03T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-medicine-uniontown-expands-robotic-assisted-surgery-with-two-da-vinci-5-systems 2026-06-03T16:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-medicine-uniontown-expands-robotic-assisted-surgery-with-two-da-vinci-5-systems 2026-06-03T16:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/an-optimistic-outlook-may-protect-the-brain-against-dementia 2026-06-03T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an-optimistic-outlook-may-protect-the-brain-against-dementia 2026-06-03T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/joyce-a-cramer-to-receive-lifetime-accelerator-award-for-transformative-contributions-to-epilepsy-research-and-therapy-development 2026-06-03T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/joyce-a-cramer-to-receive-lifetime-accelerator-award-for-transformative-contributions-to-epilepsy-research-and-therapy-development 2026-06-03T16:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/elrig-announces-keynote-lineup-for-drug-discovery-2026-marking-20-years-of-the-flagship-conference 2026-06-03T15:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elrig-announces-keynote-lineup-for-drug-discovery-2026-marking-20-years-of-the-flagship-conference 2026-06-03T15:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/kyverna-therapeutics-initiates-first-ever-rolling-bla-for-car-t-therapy-in-stiff-person-syndrome-paving-way-for-autoimmune-neurology-revolution 2026-06-03T15:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyverna-therapeutics-initiates-first-ever-rolling-bla-for-car-t-therapy-in-stiff-person-syndrome-paving-way-for-autoimmune-neurology-revolution 2026-06-03T15:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/ai-driven-drug-development-poised-to-halve-r-d-timelines-say-sanofi-and-biotech-leaders 2026-06-03T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-driven-drug-development-poised-to-halve-r-d-timelines-say-sanofi-and-biotech-leaders 2026-06-03T15:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/probio-and-gcp-clinplus-form-strategic-alliance-to-accelerate-cell-and-gene-therapy-trials-in-china 2026-06-03T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probio-and-gcp-clinplus-form-strategic-alliance-to-accelerate-cell-and-gene-therapy-trials-in-china 2026-06-03T15:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/mystery-gene-glo1-reveals-novel-anxiety-mechanism-via-methylglyoxal-and-gaba-a-receptors 2026-06-03T15:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mystery-gene-glo1-reveals-novel-anxiety-mechanism-via-methylglyoxal-and-gaba-a-receptors 2026-06-03T15:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-and-male-fertility-what-the-clinical-evidence-actually-shows 2026-06-03T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-and-male-fertility-what-the-clinical-evidence-actually-shows 2026-06-03T15:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/research-links-family-weight-comments-to-increased-eating-disorder-risk-in-adolescents 2026-06-03T14:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-links-family-weight-comments-to-increased-eating-disorder-risk-in-adolescents 2026-06-03T14:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/sotio-s-lrrc15-targeting-adc-sot106-receives-fda-orphan-drug-designation-for-osteosarcoma-treatment 2026-06-03T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sotio-s-lrrc15-targeting-adc-sot106-receives-fda-orphan-drug-designation-for-osteosarcoma-treatment 2026-06-03T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-achieves-complete-response-in-stage-four-melanoma-patient 2026-06-03T14:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-achieves-complete-response-in-stage-four-melanoma-patient 2026-06-03T14:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/musc-introduces-saint-therapy-for-rapid-depression-treatment-achieving-remission-in-days 2026-06-03T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/musc-introduces-saint-therapy-for-rapid-depression-treatment-achieving-remission-in-days 2026-06-03T13:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/brain-scans-reveal-two-distinct-biological-subtypes-of-autism 2026-06-03T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-scans-reveal-two-distinct-biological-subtypes-of-autism 2026-06-03T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/mri-biomarkers-revolutionize-clinical-trial-design-for-hereditary-ataxias 2026-06-03T13:33:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mri-biomarkers-revolutionize-clinical-trial-design-for-hereditary-ataxias 2026-06-03T13:33:30+00:00 hourly 0.9 https://trial.medpath.com/news/crc-ceo-chairs-ascp-2026-panel-on-preventable-failure-risk-in-cns-clinical-trials 2026-06-03T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crc-ceo-chairs-ascp-2026-panel-on-preventable-failure-risk-in-cns-clinical-trials 2026-06-03T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/elpasbio-completes-phase-iii-enrollment-for-allojoin-stem-cell-therapy-in-knee-osteoarthritis 2026-06-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elpasbio-completes-phase-iii-enrollment-for-allojoin-stem-cell-therapy-in-knee-osteoarthritis 2026-06-03T13:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/ucsd-researchers-develop-trace-technology-to-enhance-targeted-drug-delivery-and-reduce-side-effects 2026-06-03T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsd-researchers-develop-trace-technology-to-enhance-targeted-drug-delivery-and-reduce-side-effects 2026-06-03T13:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/biofrontera-reports-33-revenue-growth-and-nears-cash-flow-breakeven-as-ameluz-pdt-pipeline-advances 2026-06-03T12:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biofrontera-reports-33-revenue-growth-and-nears-cash-flow-breakeven-as-ameluz-pdt-pipeline-advances 2026-06-03T12:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/weinfuse-and-trial-iq-partner-to-bring-ai-driven-clinical-trials-to-community-infusion-centers 2026-06-03T12:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weinfuse-and-trial-iq-partner-to-bring-ai-driven-clinical-trials-to-community-infusion-centers 2026-06-03T12:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/axsome-therapeutics-resolves-all-sunosi-patent-litigation-securing-u-s-market-exclusivity-through-2040 2026-06-03T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axsome-therapeutics-resolves-all-sunosi-patent-litigation-securing-u-s-market-exclusivity-through-2040 2026-06-03T11:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/harmonizing-standards-and-resources-for-the-medical-genome-a-new-framework-for-clinical-genomics 2026-06-03T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harmonizing-standards-and-resources-for-the-medical-genome-a-new-framework-for-clinical-genomics 2026-06-03T11:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/pasteurized-akkermansia-muciniphila-supplement-slows-weight-regain-after-diet-induced-loss-phase-2-trial-shows 2026-06-03T11:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasteurized-akkermansia-muciniphila-supplement-slows-weight-regain-after-diet-induced-loss-phase-2-trial-shows 2026-06-03T11:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/asthma-drug-montelukast-shows-promise-in-overcoming-cancer-immunotherapy-resistance 2026-06-03T11:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asthma-drug-montelukast-shows-promise-in-overcoming-cancer-immunotherapy-resistance 2026-06-03T11:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-appoints-former-biogen-executive-dr-john-beaver-to-board-of-directors 2026-06-03T11:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-appoints-former-biogen-executive-dr-john-beaver-to-board-of-directors 2026-06-03T11:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/omnix-medical-initiates-phase-ii-trial-of-omn6-for-drug-resistant-acinetobacter-baumannii-infections 2026-06-03T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omnix-medical-initiates-phase-ii-trial-of-omn6-for-drug-resistant-acinetobacter-baumannii-infections 2026-06-03T11:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/legend-biotech-reports-promising-safety-data-for-first-in-class-cell-therapy-in-b-cell-lymphoma 2026-06-03T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/legend-biotech-reports-promising-safety-data-for-first-in-class-cell-therapy-in-b-cell-lymphoma 2026-06-03T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/gpcr-dimers-and-heteromers-emerging-therapeutic-paradigms-in-neuropsychiatric-disorders 2026-06-03T09:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gpcr-dimers-and-heteromers-emerging-therapeutic-paradigms-in-neuropsychiatric-disorders 2026-06-03T09:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/platform-trials-emerge-as-solution-to-neurological-drug-development-crisis 2026-06-03T08:05:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/platform-trials-emerge-as-solution-to-neurological-drug-development-crisis 2026-06-03T08:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/imaging-endpoints-appoints-srikanth-ayyappan-as-associate-vice-president-of-global-marketing 2026-06-03T08:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imaging-endpoints-appoints-srikanth-ayyappan-as-associate-vice-president-of-global-marketing 2026-06-03T08:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-insurance-coverage-for-behavioral-health-services-what-patients-and-providers-need-to-know 2026-06-03T07:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-insurance-coverage-for-behavioral-health-services-what-patients-and-providers-need-to-know 2026-06-03T07:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-study-on-gynecomastia-surgery-in-asian-men-reports-high-patient-satisfaction-with-tailored-surgical-techniques 2026-06-03T07:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-study-on-gynecomastia-surgery-in-asian-men-reports-high-patient-satisfaction-with-tailored-surgical-techniques 2026-06-03T07:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/memorial-sloan-kettering-highlights-patient-centered-oncology-with-profiles-of-dr-jessica-ross-and-dr-joshua-drago 2026-06-03T06:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/memorial-sloan-kettering-highlights-patient-centered-oncology-with-profiles-of-dr-jessica-ross-and-dr-joshua-drago 2026-06-03T06:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/five-minute-prayer-sessions-significantly-reduce-pain-and-anxiety-in-primary-care-patients-study-finds 2026-06-03T06:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-minute-prayer-sessions-significantly-reduce-pain-and-anxiety-in-primary-care-patients-study-finds 2026-06-03T06:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/verisim-life-formalizes-fda-collaboration-to-advance-mechanistic-ai-for-translational-drug-development 2026-06-03T06:06:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verisim-life-formalizes-fda-collaboration-to-advance-mechanistic-ai-for-translational-drug-development 2026-06-03T06:06:08+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-and-deep-learning-approaches-advance-prediction-of-drug-target-binding-and-drug-drug-interactions 2026-06-03T05:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-and-deep-learning-approaches-advance-prediction-of-drug-target-binding-and-drug-drug-interactions 2026-06-03T05:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-human-organoids-poised-to-transform-drug-testing-and-pandemic-preparedness 2026-06-03T05:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-grown-human-organoids-poised-to-transform-drug-testing-and-pandemic-preparedness 2026-06-03T05:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/ebola-outbreak-in-drc-fear-misinformation-and-conflict-hamper-containment-as-cases-surpass-340 2026-06-03T03:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebola-outbreak-in-drc-fear-misinformation-and-conflict-hamper-containment-as-cases-surpass-340 2026-06-03T03:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-esketamine-preserves-discharge-readiness-and-reduces-propofol-consumption-in-outpatient-bronchoscopy 2026-06-03T02:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-esketamine-preserves-discharge-readiness-and-reduces-propofol-consumption-in-outpatient-bronchoscopy 2026-06-03T02:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/cms-interim-final-rule-on-medicaid-work-reporting-requirements-threatens-coverage-for-cancer-patients-patient-groups-warn 2026-06-03T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-interim-final-rule-on-medicaid-work-reporting-requirements-threatens-coverage-for-cancer-patients-patient-groups-warn 2026-06-03T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/uterine-cancer-awareness-early-detection-through-abnormal-bleeding-saves-lives 2026-06-03T01:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uterine-cancer-awareness-early-detection-through-abnormal-bleeding-saves-lives 2026-06-03T01:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/sacred-heart-university-launches-connecticut-s-first-doctor-of-medical-science-program-for-practicing-physician-assistants 2026-06-03T01:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sacred-heart-university-launches-connecticut-s-first-doctor-of-medical-science-program-for-practicing-physician-assistants 2026-06-03T01:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/ilant-health-raises-15m-series-a-to-transform-obesity-care-with-ai-driven-precision-medicine 2026-06-03T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ilant-health-raises-15m-series-a-to-transform-obesity-care-with-ai-driven-precision-medicine 2026-06-03T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/hopstem-s-hnpc01-earns-fda-rmat-designation-for-chronic-stroke-expands-into-hemorrhagic-stroke-and-tbi 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hopstem-s-hnpc01-earns-fda-rmat-designation-for-chronic-stroke-expands-into-hemorrhagic-stroke-and-tbi 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-widefield-fundus-photography-combined-with-traditional-imaging-identifies-more-advanced-diabetic-retinopathy-cases 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-widefield-fundus-photography-combined-with-traditional-imaging-identifies-more-advanced-diabetic-retinopathy-cases 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-dressings-redefine-complex-wound-care-from-passive-barriers-to-microenvironment-modulating-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-hydrogel-dressings-redefine-complex-wound-care-from-passive-barriers-to-microenvironment-modulating-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-immuno-oncology-in-oral-cancer-biomarkers-novel-drug-development-and-nanoparticle-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-immuno-oncology-in-oral-cancer-biomarkers-novel-drug-development-and-nanoparticle-platforms 2026-06-03T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jackson-lab-explores-retinal-imaging-as-non-invasive-biomarker-for-early-alzheimer-s-detection 2026-06-02T23:52:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jackson-lab-explores-retinal-imaging-as-non-invasive-biomarker-for-early-alzheimer-s-detection 2026-06-02T23:52:33+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-faces-shareholder-investigation-over-alleged-fiduciary-duty-breaches 2026-06-02T23:52:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-faces-shareholder-investigation-over-alleged-fiduciary-duty-breaches 2026-06-02T23:52:04+00:00 hourly 0.9 https://trial.medpath.com/news/upstream-bio-to-present-novel-tslp-antagonist-verekitug-at-goldman-sachs-healthcare-conference 2026-06-02T23:51:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upstream-bio-to-present-novel-tslp-antagonist-verekitug-at-goldman-sachs-healthcare-conference 2026-06-02T23:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/high-q-technologies-and-creative-biostructure-form-strategic-partnership-to-advance-quantum-epr-spectroscopy-in-drug-discovery 2026-06-02T23:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-q-technologies-and-creative-biostructure-form-strategic-partnership-to-advance-quantum-epr-spectroscopy-in-drug-discovery 2026-06-02T23:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/trabectedin-plus-radiotherapy-shows-promise-in-retroperitoneal-sarcoma-treatment 2026-06-02T23:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trabectedin-plus-radiotherapy-shows-promise-in-retroperitoneal-sarcoma-treatment 2026-06-02T23:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-s-il-17-inhibitor-lecankitug-nears-second-indication-as-nmpa-accepts-ankylosing-spondylitis-application 2026-06-02T23:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livzon-s-il-17-inhibitor-lecankitug-nears-second-indication-as-nmpa-accepts-ankylosing-spondylitis-application 2026-06-02T23:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/allen-institute-launches-400m-brain-health-accelerator-to-develop-precision-genetic-therapies-for-neurodegenerative-diseases 2026-06-02T23:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allen-institute-launches-400m-brain-health-accelerator-to-develop-precision-genetic-therapies-for-neurodegenerative-diseases 2026-06-02T23:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/psychedelic-trials-face-a-methodological-reckoning-as-blinding-failures-and-design-gaps-threaten-regulatory-success 2026-06-02T23:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychedelic-trials-face-a-methodological-reckoning-as-blinding-failures-and-design-gaps-threaten-regulatory-success 2026-06-02T23:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/a-synuclein-saa-and-mri-imaging-provide-distinct-complementary-information-in-early-parkinson-s-disease-new-study-finds 2026-06-02T23:46:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-synuclein-saa-and-mri-imaging-provide-distinct-complementary-information-in-early-parkinson-s-disease-new-study-finds 2026-06-02T23:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/moonlight-therapeutics-launches-first-in-human-trial-of-microneedle-peanut-allergy-treatment 2026-06-02T23:46:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moonlight-therapeutics-launches-first-in-human-trial-of-microneedle-peanut-allergy-treatment 2026-06-02T23:46:33+00:00 hourly 0.9 https://trial.medpath.com/news/first-leishmaniasis-vaccine-using-crispr-gene-editing-clears-fda-hurdle-phase-1-trial-set-to-begin 2026-06-02T23:45:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-leishmaniasis-vaccine-using-crispr-gene-editing-clears-fda-hurdle-phase-1-trial-set-to-begin 2026-06-02T23:45:43+00:00 hourly 0.9 https://trial.medpath.com/news/imu-biosciences-raises-53m-to-advance-ai-driven-immune-system-profiling-platform 2026-06-02T23:45:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imu-biosciences-raises-53m-to-advance-ai-driven-immune-system-profiling-platform 2026-06-02T23:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-advances-opaganib-for-bundibugyo-ebola-outbreak-as-cases-surpass-3200 2026-06-02T23:44:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-advances-opaganib-for-bundibugyo-ebola-outbreak-as-cases-surpass-3200 2026-06-02T23:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/urogen-pharma-settles-patent-litigation-with-teva-secures-jelmyto-protection-until-2030 2026-06-02T23:44:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/urogen-pharma-settles-patent-litigation-with-teva-secures-jelmyto-protection-until-2030 2026-06-02T23:44:46+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-pauses-epilepsy-drug-development-after-phase-2-3-trial-misses-primary-endpoint 2026-06-02T23:43:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-pauses-epilepsy-drug-development-after-phase-2-3-trial-misses-primary-endpoint 2026-06-02T23:43:22+00:00 hourly 0.9 https://trial.medpath.com/news/techbio-company-lucera-launches-with-ai-powered-platform-to-transform-pharmaceutical-r-d-decision-making 2026-06-02T23:40:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/techbio-company-lucera-launches-with-ai-powered-platform-to-transform-pharmaceutical-r-d-decision-making 2026-06-02T23:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/a-trojan-horse-for-brain-cancer-first-in-human-gene-therapy-trial-shows-promise-in-glioblastoma 2026-06-02T23:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-trojan-horse-for-brain-cancer-first-in-human-gene-therapy-trial-shows-promise-in-glioblastoma 2026-06-02T23:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/correctsequence-s-base-editing-therapy-cs-206-shows-15-month-voc-free-success-in-sickle-cell-disease-patient 2026-06-02T23:38:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/correctsequence-s-base-editing-therapy-cs-206-shows-15-month-voc-free-success-in-sickle-cell-disease-patient 2026-06-02T23:38:50+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-based-personalized-cancer-treatment-meets-goals-in-late-stage-melanoma-trial 2026-06-02T23:37:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-based-personalized-cancer-treatment-meets-goals-in-late-stage-melanoma-trial 2026-06-02T23:37:16+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-s-mn-166-ibudilast-advances-toward-pivotal-als-data-as-phase-2b-3-combat-als-trial-completes-enrollment 2026-06-02T23:37:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-s-mn-166-ibudilast-advances-toward-pivotal-als-data-as-phase-2b-3-combat-als-trial-completes-enrollment 2026-06-02T23:37:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-safety-concerns-force-fulcrum-therapeutics-to-halt-sickle-cell-drug-development 2026-06-02T23:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-safety-concerns-force-fulcrum-therapeutics-to-halt-sickle-cell-drug-development 2026-06-02T23:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/passage-bio-and-remix-therapeutics-announce-merger-to-advance-rem-422-an-oral-mrna-degrader-targeting-myb-in-cancer 2026-06-02T23:29:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/passage-bio-and-remix-therapeutics-announce-merger-to-advance-rem-422-an-oral-mrna-degrader-targeting-myb-in-cancer 2026-06-02T23:29:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-eit-pharma-s-nda-for-lonafarnib-first-oral-therapy-candidate-for-chronic-hepatitis-d 2026-06-02T23:29:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-eit-pharma-s-nda-for-lonafarnib-first-oral-therapy-candidate-for-chronic-hepatitis-d 2026-06-02T23:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/vaderis-raises-152-million-to-fund-phase-3-trial-of-akt-inhibitor-engasertib-in-hereditary-haemorrhagic-telangiectasia 2026-06-02T23:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaderis-raises-152-million-to-fund-phase-3-trial-of-akt-inhibitor-engasertib-in-hereditary-haemorrhagic-telangiectasia 2026-06-02T23:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/xenetic-biosciences-reports-dnase-i-enhances-car-t-cell-persistence-and-survival-in-asco-2026-data 2026-06-02T23:29:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xenetic-biosciences-reports-dnase-i-enhances-car-t-cell-persistence-and-survival-in-asco-2026-data 2026-06-02T23:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/zoetis-lenivia-gains-uk-approval-as-first-quarterly-anti-ngf-monoclonal-antibody-for-canine-osteoarthritis-pain 2026-06-02T23:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zoetis-lenivia-gains-uk-approval-as-first-quarterly-anti-ngf-monoclonal-antibody-for-canine-osteoarthritis-pain 2026-06-02T23:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/eccogene-and-astrazeneca-to-present-elecoglipron-clinical-data-at-ada-2026 2026-06-02T23:28:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eccogene-and-astrazeneca-to-present-elecoglipron-clinical-data-at-ada-2026 2026-06-02T23:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-cipepofol-becomes-first-chinese-developed-anesthetic-to-receive-fda-approval 2026-06-02T23:25:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-cipepofol-becomes-first-chinese-developed-anesthetic-to-receive-fda-approval 2026-06-02T23:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/intravacc-and-primrose-bio-renew-strategic-partnership-to-advance-conjugate-vaccine-development 2026-06-02T23:24:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intravacc-and-primrose-bio-renew-strategic-partnership-to-advance-conjugate-vaccine-development 2026-06-02T23:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-reports-positive-phase-3-results-for-remibrutinib-in-multiple-sclerosis 2026-06-02T23:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-reports-positive-phase-3-results-for-remibrutinib-in-multiple-sclerosis 2026-06-02T23:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/cbo-calls-for-urgent-research-as-no-surprises-act-dispute-data-signals-rising-healthcare-costs 2026-06-02T21:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbo-calls-for-urgent-research-as-no-surprises-act-dispute-data-signals-rising-healthcare-costs 2026-06-02T21:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/medical-evacuation-and-repatriation-what-singaporean-travellers-need-to-know 2026-06-02T18:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medical-evacuation-and-repatriation-what-singaporean-travellers-need-to-know 2026-06-02T18:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/training-and-exercise-as-drivers-of-poststroke-neural-repair-mechanisms-and-clinical-translation 2026-06-02T17:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/training-and-exercise-as-drivers-of-poststroke-neural-repair-mechanisms-and-clinical-translation 2026-06-02T17:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-cancer-screening-promise-pitfalls-and-the-question-of-mortality-benefit 2026-06-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-cancer-screening-promise-pitfalls-and-the-question-of-mortality-benefit 2026-06-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancell-raises-315m-series-d-to-advance-targeted-alpha-radiopharmaceuticals-for-cancer 2026-06-02T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancell-raises-315m-series-d-to-advance-targeted-alpha-radiopharmaceuticals-for-cancer 2026-06-02T15:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/rfk-jr-s-hhs-guidelines-on-ssris-spark-fierce-backlash-from-psychiatric-community 2026-06-02T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rfk-jr-s-hhs-guidelines-on-ssris-spark-fierce-backlash-from-psychiatric-community 2026-06-02T15:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-reveals-dopamine-system-injury-not-widespread-inflammation-as-hallmark-of-long-covid-brain-pathology 2026-06-02T15:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pet-imaging-reveals-dopamine-system-injury-not-widespread-inflammation-as-hallmark-of-long-covid-brain-pathology 2026-06-02T15:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/app-based-symptom-monitoring-improves-quality-of-life-in-advanced-cancer-two-randomized-trials 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/app-based-symptom-monitoring-improves-quality-of-life-in-advanced-cancer-two-randomized-trials 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-survivors-day-2026-five-year-survival-rate-reaches-historic-70-as-research-driven-survivorship-care-gains-momentum 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-cancer-survivors-day-2026-five-year-survival-rate-reaches-historic-70-as-research-driven-survivorship-care-gains-momentum 2026-06-02T14:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/genetics-of-parkinson-disease-paradigm-shifts-and-future-prospects 2026-06-02T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetics-of-parkinson-disease-paradigm-shifts-and-future-prospects 2026-06-02T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-laboratories-vs-intuitive-surgical-divergent-strategies-in-medtech-for-2026 2026-06-02T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-laboratories-vs-intuitive-surgical-divergent-strategies-in-medtech-for-2026 2026-06-02T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/2026-medicare-part-a-hospital-deductible-reaches-1736-per-benefit-period-posing-significant-financial-risk-for-beneficiaries 2026-06-02T05:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-medicare-part-a-hospital-deductible-reaches-1736-per-benefit-period-posing-significant-financial-risk-for-beneficiaries 2026-06-02T05:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/therapeutic-activation-of-the-cgas-sting-pathway-emerging-strategies-for-antitumor-immunotherapy-and-antiviral-defense 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therapeutic-activation-of-the-cgas-sting-pathway-emerging-strategies-for-antitumor-immunotherapy-and-antiviral-defense 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/antarctic-sea-squirt-compound-shows-selective-melanoma-killing-activity-in-usf-led-expedition 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antarctic-sea-squirt-compound-shows-selective-melanoma-killing-activity-in-usf-led-expedition 2026-06-02T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/edap-reports-record-hifu-revenue-in-q4-2025-fda-cleared-next-gen-focal-one-platform-drives-34-growth 2026-06-01T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edap-reports-record-hifu-revenue-in-q4-2025-fda-cleared-next-gen-focal-one-platform-drives-34-growth 2026-06-01T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-s-zoci-demonstrates-62-5-intracranial-orr-in-small-cell-lung-cancer-global-bla-submission-planned-for-late-2027 2026-06-01T19:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-s-zoci-demonstrates-62-5-intracranial-orr-in-small-cell-lung-cancer-global-bla-submission-planned-for-late-2027 2026-06-01T19:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/could-you-patent-the-sun-the-story-behind-jonas-salk-s-decision-to-forgo-the-polio-vaccine-patent 2026-06-01T16:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-you-patent-the-sun-the-story-behind-jonas-salk-s-decision-to-forgo-the-polio-vaccine-patent 2026-06-01T16:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/cbih-builds-cannabinoid-psilocybin-research-platform-for-ptsd-targeting-memory-and-emotional-regulation-pathways 2026-06-01T15:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cbih-builds-cannabinoid-psilocybin-research-platform-for-ptsd-targeting-memory-and-emotional-regulation-pathways 2026-06-01T15:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/pathology-driven-biomarkers-emerge-as-critical-tools-for-predicting-immunotherapy-response-in-solid-tumors 2026-06-01T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathology-driven-biomarkers-emerge-as-critical-tools-for-predicting-immunotherapy-response-in-solid-tumors 2026-06-01T14:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapy-development 2026-06-01T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-draft-guidance-aims-to-accelerate-cell-and-gene-therapy-development 2026-06-01T14:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-appoints-radiotherapy-expert-steffen-heeger-as-chief-medical-officer 2026-06-01T14:07:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-appoints-radiotherapy-expert-steffen-heeger-as-chief-medical-officer 2026-06-01T14:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/oak-hill-bio-to-go-public-via-spac-merger-secures-175-million-to-advance-rugonersen-for-angelman-syndrome-through-phase-3 2026-06-01T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oak-hill-bio-to-go-public-via-spac-merger-secures-175-million-to-advance-rugonersen-for-angelman-syndrome-through-phase-3 2026-06-01T14:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twins-of-the-brain-personalized-computational-models-poised-to-transform-neurological-and-psychiatric-treatment 2026-06-01T13:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-twins-of-the-brain-personalized-computational-models-poised-to-transform-neurological-and-psychiatric-treatment 2026-06-01T13:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/purdue-s-desi-ms-platform-accelerates-cancer-drug-discovery-with-integrated-synthesis-to-screening-workflow 2026-06-01T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/purdue-s-desi-ms-platform-accelerates-cancer-drug-discovery-with-integrated-synthesis-to-screening-workflow 2026-06-01T13:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/elite-pharmaceuticals-files-anda-for-generic-anticoagulant-targeting-26-billion-market 2026-06-01T13:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elite-pharmaceuticals-files-anda-for-generic-anticoagulant-targeting-26-billion-market 2026-06-01T13:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-receives-fda-clearance-for-next-generation-il-12-tethered-til-therapy-trial 2026-06-01T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-receives-fda-clearance-for-next-generation-il-12-tethered-til-therapy-trial 2026-06-01T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/aclarion-s-nociscan-technology-reveals-immune-biomarkers-in-chronic-back-pain-expanding-beyond-surgical-planning 2026-06-01T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclarion-s-nociscan-technology-reveals-immune-biomarkers-in-chronic-back-pain-expanding-beyond-surgical-planning 2026-06-01T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/waters-unveils-two-next-generation-mass-spectrometers-at-asms-2026-setting-new-benchmarks-for-multiomics-and-structural-biology 2026-06-01T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/waters-unveils-two-next-generation-mass-spectrometers-at-asms-2026-setting-new-benchmarks-for-multiomics-and-structural-biology 2026-06-01T12:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/rejuvenate-biomed-completes-patient-recruitment-for-phase-2-trial-of-first-in-class-sarcopenia-drug-rjx-01 2026-06-01T12:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rejuvenate-biomed-completes-patient-recruitment-for-phase-2-trial-of-first-in-class-sarcopenia-drug-rjx-01 2026-06-01T12:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-receives-fda-approval-for-in-house-rabies-virus-neutralization-testing-laboratory 2026-06-01T12:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-receives-fda-approval-for-in-house-rabies-virus-neutralization-testing-laboratory 2026-06-01T12:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-nouscom-s-nous-209-for-lynch-syndrome-cancer-prevention 2026-06-01T12:07:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-nouscom-s-nous-209-for-lynch-syndrome-cancer-prevention 2026-06-01T12:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-advances-three-solid-tumor-programs-with-promising-asco-2026-data 2026-06-01T12:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-advances-three-solid-tumor-programs-with-promising-asco-2026-data 2026-06-01T12:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/biond-biologics-secures-8m-investment-from-gibf-to-advance-novel-immunotherapies-in-china 2026-06-01T12:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biond-biologics-secures-8m-investment-from-gibf-to-advance-novel-immunotherapies-in-china 2026-06-01T12:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/online-resources-on-ai-and-cancer-care-are-scarce-poor-quality-and-omit-critical-safety-risks-study-finds 2026-06-01T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/online-resources-on-ai-and-cancer-care-are-scarce-poor-quality-and-omit-critical-safety-risks-study-finds 2026-06-01T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-satri-cel-shows-durable-survival-benefit-in-advanced-gastric-cancer-with-4-5-year-follow-up 2026-06-01T05:07:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-satri-cel-shows-durable-survival-benefit-in-advanced-gastric-cancer-with-4-5-year-follow-up 2026-06-01T05:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-secures-1-26-billion-licensing-deal-for-hanmi-s-glp-2-drug-sonefpeglutide 2026-06-01T05:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-secures-1-26-billion-licensing-deal-for-hanmi-s-glp-2-drug-sonefpeglutide 2026-06-01T05:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-s-ai-designed-peptide-receives-us-safety-certification-while-pan-tead-inhibitor-advances-to-clinical-trials 2026-06-01T05:05:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalpi-s-ai-designed-peptide-receives-us-safety-certification-while-pan-tead-inhibitor-advances-to-clinical-trials 2026-06-01T05:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/korean-pharmaceutical-companies-launch-new-low-dose-pitavastatin-combination-therapies-for-dyslipidemia-management 2026-06-01T05:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-pharmaceutical-companies-launch-new-low-dose-pitavastatin-combination-therapies-for-dyslipidemia-management 2026-06-01T05:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-brain-decoding-of-spontaneous-pain-offers-path-to-objective-biomarkers-in-chronic-pain 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-brain-decoding-of-spontaneous-pain-offers-path-to-objective-biomarkers-in-chronic-pain 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/unraveling-the-mechanisms-of-cardiovascular-aging-from-molecular-drivers-to-therapeutic-strategies 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unraveling-the-mechanisms-of-cardiovascular-aging-from-molecular-drivers-to-therapeutic-strategies 2026-06-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abemaciclib-demonstrates-significant-efficacy-in-phase-3-trial-for-rare-dedifferentiated-liposarcoma 2026-05-31T21:40:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abemaciclib-demonstrates-significant-efficacy-in-phase-3-trial-for-rare-dedifferentiated-liposarcoma 2026-05-31T21:40:03+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-erleada-shows-dramatic-efficacy-in-high-risk-prostate-cancer-surgery-trial 2026-05-31T21:27:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-erleada-shows-dramatic-efficacy-in-high-risk-prostate-cancer-surgery-trial 2026-05-31T21:27:20+00:00 hourly 0.9 https://trial.medpath.com/news/circadian-timing-of-immunotherapy-may-influence-outcomes-in-triple-negative-breast-cancer-based-on-tumor-immune-microenvironment 2026-05-31T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circadian-timing-of-immunotherapy-may-influence-outcomes-in-triple-negative-breast-cancer-based-on-tumor-immune-microenvironment 2026-05-31T21:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/2026-china-nrdl-negotiations-record-submissions-pre-approval-access-and-the-rise-of-adcs-car-t-and-bispecific-antibodies 2026-05-31T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2026-china-nrdl-negotiations-record-submissions-pre-approval-access-and-the-rise-of-adcs-car-t-and-bispecific-antibodies 2026-05-31T21:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bemotrizinol-first-new-sunscreen-ingredient-in-over-20-years 2026-05-31T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bemotrizinol-first-new-sunscreen-ingredient-in-over-20-years 2026-05-31T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/amivantamab-shows-unprecedented-response-rates-in-treatment-resistant-head-and-neck-cancer 2026-05-31T08:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amivantamab-shows-unprecedented-response-rates-in-treatment-resistant-head-and-neck-cancer 2026-05-31T08:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bemotrizinol-for-sunscreens-as-dermatologists-warn-against-tanmaxxing-social-media-trend 2026-05-31T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bemotrizinol-for-sunscreens-as-dermatologists-warn-against-tanmaxxing-social-media-trend 2026-05-31T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leflunomide-hydroxychloroquine-combination-shows-efficacy-in-systemic-sjogren-s-disease-in-phase-2b-trial 2026-05-30T22:09:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leflunomide-hydroxychloroquine-combination-shows-efficacy-in-systemic-sjogren-s-disease-in-phase-2b-trial 2026-05-30T22:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-a-dream-trial-41-of-exceptional-responders-remain-off-adt-at-18-months-in-metastatic-prostate-cancer 2026-05-30T21:20:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-a-dream-trial-41-of-exceptional-responders-remain-off-adt-at-18-months-in-metastatic-prostate-cancer 2026-05-30T21:20:32+00:00 hourly 0.9 https://trial.medpath.com/news/actinium-pharmaceuticals-secures-canadian-patent-protection-for-radiotherapy-programs-in-aml-and-cell-therapy-conditioning 2026-05-30T19:44:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-secures-canadian-patent-protection-for-radiotherapy-programs-in-aml-and-cell-therapy-conditioning 2026-05-30T19:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/scit-demonstrates-superior-igg4-and-treg-induction-versus-slit-in-house-dust-mite-allergy-study-finds 2026-05-30T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scit-demonstrates-superior-igg4-and-treg-induction-versus-slit-in-house-dust-mite-allergy-study-finds 2026-05-30T19:34:21+00:00 hourly 0.9 https://trial.medpath.com/news/senomac-trial-confirms-omitting-axillary-lymph-node-dissection-is-safe-for-breast-cancer-patients-with-sentinel-node-macrometastases 2026-05-30T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senomac-trial-confirms-omitting-axillary-lymph-node-dissection-is-safe-for-breast-cancer-patients-with-sentinel-node-macrometastases 2026-05-30T19:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/cabometyx-shows-significant-efficacy-in-both-functional-and-non-functional-neuroendocrine-tumors 2026-05-30T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cabometyx-shows-significant-efficacy-in-both-functional-and-non-functional-neuroendocrine-tumors 2026-05-30T19:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/implanted-radiation-tiles-double-survival-in-brain-metastasis-patients-phase-3-trial-shows 2026-05-30T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implanted-radiation-tiles-double-survival-in-brain-metastasis-patients-phase-3-trial-shows 2026-05-30T19:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/chmp-recommends-eu-approval-of-roche-s-susvimo-first-continuous-delivery-treatment-for-neovascular-amd 2026-05-30T19:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chmp-recommends-eu-approval-of-roche-s-susvimo-first-continuous-delivery-treatment-for-neovascular-amd 2026-05-30T19:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-anselamimab-shows-62-survival-improvement-in-kappa-light-chain-amyloidosis-despite-missing-primary-endpoint 2026-05-30T19:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-anselamimab-shows-62-survival-improvement-in-kappa-light-chain-amyloidosis-despite-missing-primary-endpoint 2026-05-30T19:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/kelun-biotech-s-lunbotinib-fumarate-shows-promising-phase-ii-results-in-ret-fusion-positive-nsclc 2026-05-30T19:28:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kelun-biotech-s-lunbotinib-fumarate-shows-promising-phase-ii-results-in-ret-fusion-positive-nsclc 2026-05-30T19:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/tafasitamab-lenalidomide-combination-reduces-disease-progression-risk-by-25-in-high-risk-aggressive-b-cell-lymphomas 2026-05-30T19:27:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tafasitamab-lenalidomide-combination-reduces-disease-progression-risk-by-25-in-high-risk-aggressive-b-cell-lymphomas 2026-05-30T19:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-test-enables-thousands-of-breast-cancer-patients-to-safely-skip-chemotherapy 2026-05-30T19:22:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-test-enables-thousands-of-breast-cancer-patients-to-safely-skip-chemotherapy 2026-05-30T19:22:45+00:00 hourly 0.9 https://trial.medpath.com/news/otsuka-s-centanafadine-shows-promise-for-executive-function-and-emotional-regulation-in-adult-adhd 2026-05-30T19:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otsuka-s-centanafadine-shows-promise-for-executive-function-and-emotional-regulation-in-adult-adhd 2026-05-30T19:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-corporation-receives-fda-approval-for-afrezza-inhaled-insulin-in-pediatric-diabetes-patients 2026-05-30T19:20:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-corporation-receives-fda-approval-for-afrezza-inhaled-insulin-in-pediatric-diabetes-patients 2026-05-30T19:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/google-co-scientist-multi-agent-ai-system-validated-in-nature-preclinical-hypotheses-confirmed-in-aml-and-liver-fibrosis-public-registration-opens 2026-05-30T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-co-scientist-multi-agent-ai-system-validated-in-nature-preclinical-hypotheses-confirmed-in-aml-and-liver-fibrosis-public-registration-opens 2026-05-30T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/whitehawk-therapeutics-validates-sez6-as-high-expression-target-for-small-cell-lung-cancer-adc-development 2026-05-30T18:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whitehawk-therapeutics-validates-sez6-as-high-expression-target-for-small-cell-lung-cancer-adc-development 2026-05-30T18:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/rybrevant-plus-lazcluze-achieves-nearly-3-5-year-median-overall-survival-in-atypical-egfr-mutated-nsclc 2026-05-30T18:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rybrevant-plus-lazcluze-achieves-nearly-3-5-year-median-overall-survival-in-atypical-egfr-mutated-nsclc 2026-05-30T18:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-secures-patent-for-novel-coronavirus-treatment-targeting-viral-immune-suppression 2026-05-30T18:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-secures-patent-for-novel-coronavirus-treatment-targeting-viral-immune-suppression 2026-05-30T18:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/holmusk-expands-neuroblu-real-world-data-platform-to-46-million-patients-with-alzheimer-s-biomarker-and-neurological-outcomes-depth 2026-05-30T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/holmusk-expands-neuroblu-real-world-data-platform-to-46-million-patients-with-alzheimer-s-biomarker-and-neurological-outcomes-depth 2026-05-30T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/neuropace-receives-fda-approval-for-ai-powered-ecog-assistant-to-enhance-epilepsy-care 2026-05-30T13:06:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuropace-receives-fda-approval-for-ai-powered-ecog-assistant-to-enhance-epilepsy-care 2026-05-30T13:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/asco-partners-with-ryght-ai-to-accelerate-site-selection-for-metastatic-breast-cancer-cdk4-6-inhibitor-trial 2026-05-30T13:06:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-partners-with-ryght-ai-to-accelerate-site-selection-for-metastatic-breast-cancer-cdk4-6-inhibitor-trial 2026-05-30T13:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-july-2026-preview-key-decisions-spanning-oncology-nephrology-and-cardiology 2026-05-30T12:07:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-july-2026-preview-key-decisions-spanning-oncology-nephrology-and-cardiology 2026-05-30T12:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/conexeu-sciences-initiates-preclinical-3d-bioprinted-breast-matrix-program-with-wake-forest-institute-for-regenerative-medicine 2026-05-30T05:06:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conexeu-sciences-initiates-preclinical-3d-bioprinted-breast-matrix-program-with-wake-forest-institute-for-regenerative-medicine 2026-05-30T05:06:30+00:00 hourly 0.9 https://trial.medpath.com/news/rezdiffra-demonstrates-cardiovascular-and-liver-risk-reduction-in-mash-patients 2026-05-30T03:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezdiffra-demonstrates-cardiovascular-and-liver-risk-reduction-in-mash-patients 2026-05-30T03:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-advances-first-in-class-quadruple-action-obesity-drug-ct-g32-into-primate-toxicology-studies 2026-05-30T03:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-advances-first-in-class-quadruple-action-obesity-drug-ct-g32-into-primate-toxicology-studies 2026-05-30T03:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/exercise-in-early-to-middle-adulthood-may-slow-brain-aging-study-finds 2026-05-30T02:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exercise-in-early-to-middle-adulthood-may-slow-brain-aging-study-finds 2026-05-30T02:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-coredio-breakthrough-designation-for-ai-powered-heart-failure-monitoring-platform 2026-05-30T02:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-coredio-breakthrough-designation-for-ai-powered-heart-failure-monitoring-platform 2026-05-30T02:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/shine-technologies-secures-european-marketing-authorization-for-lutetium-177-radioisotope-ilumira 2026-05-30T02:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shine-technologies-secures-european-marketing-authorization-for-lutetium-177-radioisotope-ilumira 2026-05-30T02:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/most-favored-nation-drug-pricing-proposal-threatens-patient-access-and-pharmaceutical-innovation-experts-warn 2026-05-29T19:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/most-favored-nation-drug-pricing-proposal-threatens-patient-access-and-pharmaceutical-innovation-experts-warn 2026-05-29T19:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharma-m-a-surge-drives-intensified-demand-for-specialized-legal-talent 2026-05-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharma-m-a-surge-drives-intensified-demand-for-specialized-legal-talent 2026-05-29T16:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-and-africa-cdc-prioritize-experimental-ebola-treatments-and-vaccines-for-bundibugyo-strain-amid-drc-outbreak 2026-05-29T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-and-africa-cdc-prioritize-experimental-ebola-treatments-and-vaccines-for-bundibugyo-strain-amid-drc-outbreak 2026-05-29T15:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/pcos-officially-renamed-to-pmos-landmark-lancet-publication-caps-decade-long-global-consensus-process 2026-05-29T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcos-officially-renamed-to-pmos-landmark-lancet-publication-caps-decade-long-global-consensus-process 2026-05-29T12:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/nucs-ai-partners-with-astrazeneca-to-develop-ai-driven-response-prediction-for-psma-targeted-radioconjugates 2026-05-29T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucs-ai-partners-with-astrazeneca-to-develop-ai-driven-response-prediction-for-psma-targeted-radioconjugates 2026-05-29T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/biological-age-estimation-tools-show-promise-for-early-risk-detection-but-clinical-translation-requires-further-validation 2026-05-29T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biological-age-estimation-tools-show-promise-for-early-risk-detection-but-clinical-translation-requires-further-validation 2026-05-29T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-medication-when-and-how-blood-pressure-drugs-can-be-safely-reduced 2026-05-29T11:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-medication-when-and-how-blood-pressure-drugs-can-be-safely-reduced 2026-05-29T11:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/340b-drug-pricing-program-reform-california-s-opportunity-to-lead-on-transparency-and-accountability 2026-05-29T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/340b-drug-pricing-program-reform-california-s-opportunity-to-lead-on-transparency-and-accountability 2026-05-29T11:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-discontinues-blood-cancer-drug-tebapivat-after-phase-2-trial-failure 2026-05-29T11:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-pharmaceuticals-discontinues-blood-cancer-drug-tebapivat-after-phase-2-trial-failure 2026-05-29T11:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-and-france-launch-landmark-biomedical-and-ai-health-alliance-to-accelerate-research-on-major-diseases 2026-05-29T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-and-france-launch-landmark-biomedical-and-ai-health-alliance-to-accelerate-research-on-major-diseases 2026-05-29T08:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-biologics-and-pfizer-forge-10-5-billion-strategic-collaboration-for-12-novel-cancer-programs 2026-05-29T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-biologics-and-pfizer-forge-10-5-billion-strategic-collaboration-for-12-novel-cancer-programs 2026-05-29T08:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/mountain-valley-md-advances-quicksometm-sublingual-delivery-platform-for-compounded-peptides-reports-formulation-progress-across-bpc-157-retatrutide-and-others 2026-05-29T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mountain-valley-md-advances-quicksometm-sublingual-delivery-platform-for-compounded-peptides-reports-formulation-progress-across-bpc-157-retatrutide-and-others 2026-05-29T07:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-recommends-regeneron-s-maftivimab-for-clinical-trials-against-bundibugyo-ebolavirus-outbreak 2026-05-29T07:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-recommends-regeneron-s-maftivimab-for-clinical-trials-against-bundibugyo-ebolavirus-outbreak 2026-05-29T07:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-presents-real-world-safety-data-on-trastuzumab-deruxtecan-at-asco-2026 2026-05-29T07:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parexel-presents-real-world-safety-data-on-trastuzumab-deruxtecan-at-asco-2026 2026-05-29T07:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/parse-biosciences-and-bit-bio-form-strategic-alliance-to-map-cell-identity-for-ai-driven-drug-discovery 2026-05-29T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parse-biosciences-and-bit-bio-form-strategic-alliance-to-map-cell-identity-for-ai-driven-drug-discovery 2026-05-29T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/bpgbio-to-present-phase-2-data-on-novel-mitochondrial-targeted-therapy-bpm31510-for-glioblastoma-at-asco-2026 2026-05-29T05:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bpgbio-to-present-phase-2-data-on-novel-mitochondrial-targeted-therapy-bpm31510-for-glioblastoma-at-asco-2026 2026-05-29T05:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/treos-bio-reports-six-year-cancer-free-survival-in-mss-mcrc-patient-treated-with-polypepi1018-off-the-shelf-immunotherapy 2026-05-29T05:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treos-bio-reports-six-year-cancer-free-survival-in-mss-mcrc-patient-treated-with-polypepi1018-off-the-shelf-immunotherapy 2026-05-29T05:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/procept-biorobotics-completes-water-iv-prostate-cancer-study-enrollment-receives-fda-approval-for-second-trial 2026-05-29T05:08:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/procept-biorobotics-completes-water-iv-prostate-cancer-study-enrollment-receives-fda-approval-for-second-trial 2026-05-29T05:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/rest-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-novel-early-ptsd-intervention-rst-101 2026-05-29T05:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rest-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-novel-early-ptsd-intervention-rst-101 2026-05-29T05:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/alzprotect-receives-fda-clearance-for-azp2006-in-progressive-supranuclear-palsy 2026-05-29T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzprotect-receives-fda-clearance-for-azp2006-in-progressive-supranuclear-palsy 2026-05-29T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/nuclidium-raises-eur115-million-to-advance-copper-based-radiotheranostics-for-prostate-and-breast-cancer 2026-05-29T05:07:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclidium-raises-eur115-million-to-advance-copper-based-radiotheranostics-for-prostate-and-breast-cancer 2026-05-29T05:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/delix-therapeutics-novel-neuroplastogen-zalsupindole-shows-no-cognitive-impairment-in-phase-1b-depression-trial 2026-05-29T04:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delix-therapeutics-novel-neuroplastogen-zalsupindole-shows-no-cognitive-impairment-in-phase-1b-depression-trial 2026-05-29T04:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-panel-votes-to-update-covid-19-vaccines-to-target-xfg-variant-for-2026-2027-season 2026-05-29T03:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-panel-votes-to-update-covid-19-vaccines-to-target-xfg-variant-for-2026-2027-season 2026-05-29T03:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-therapeutics-receives-fda-priority-review-for-saroglitazar-in-primary-biliary-cholangitis 2026-05-29T03:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-therapeutics-receives-fda-priority-review-for-saroglitazar-in-primary-biliary-cholangitis 2026-05-29T03:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/quotient-sciences-initiates-first-clinical-trial-of-ai-designed-drug-formulation 2026-05-29T03:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quotient-sciences-initiates-first-clinical-trial-of-ai-designed-drug-formulation 2026-05-29T03:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/nestle-and-idb-holding-partner-to-bring-vowst-live-biotherapeutic-to-european-markets 2026-05-29T03:06:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nestle-and-idb-holding-partner-to-bring-vowst-live-biotherapeutic-to-european-markets 2026-05-29T03:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-s-btk-inhibitor-orelabrutinib-receives-new-drug-application-acceptance-in-china-for-primary-immune-thrombocytopenia-treatment 2026-05-29T02:07:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-s-btk-inhibitor-orelabrutinib-receives-new-drug-application-acceptance-in-china-for-primary-immune-thrombocytopenia-treatment 2026-05-29T02:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/pepromene-bio-s-baff-r-car-t-therapy-shows-78-complete-response-rate-in-b-cell-lymphoma-patients-after-cd19-car-t-failure 2026-05-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pepromene-bio-s-baff-r-car-t-therapy-shows-78-complete-response-rate-in-b-cell-lymphoma-patients-after-cd19-car-t-failure 2026-05-29T02:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-s-novel-sos1-inhibitor-lnp8701-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2026-05-29T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-s-novel-sos1-inhibitor-lnp8701-shows-promising-safety-profile-in-phase-1-solid-tumor-trial 2026-05-29T02:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/salvectors-oncolytic-bacteria-therapy-yb1-x7-receives-dual-ind-clearance-in-us-and-china 2026-05-29T02:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salvectors-oncolytic-bacteria-therapy-yb1-x7-receives-dual-ind-clearance-in-us-and-china 2026-05-29T02:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/aptevo-and-niowave-form-strategic-partnership-to-develop-radiopharmaceutical-cancer-therapies 2026-05-29T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptevo-and-niowave-form-strategic-partnership-to-develop-radiopharmaceutical-cancer-therapies 2026-05-29T00:09:32+00:00 hourly 0.9 https://trial.medpath.com/news/repairon-s-engineered-heart-muscle-patches-show-promise-in-advanced-heart-failure-trial-published-in-nejm 2026-05-29T00:08:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repairon-s-engineered-heart-muscle-patches-show-promise-in-advanced-heart-failure-trial-published-in-nejm 2026-05-29T00:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-receives-fda-orphan-drug-designation-for-watch-and-wait-indolent-non-hodgkin-lymphoma 2026-05-29T00:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-s-eo2463-receives-fda-orphan-drug-designation-for-watch-and-wait-indolent-non-hodgkin-lymphoma 2026-05-29T00:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/ai-transcription-tools-in-healthcare-navigating-the-legal-and-compliance-minefield 2026-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-transcription-tools-in-healthcare-navigating-the-legal-and-compliance-minefield 2026-05-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/octozi-raises-3m-to-deploy-agentic-ai-in-clinical-trial-data-operations-demonstrates-six-fold-throughput-gains 2026-05-28T22:08:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/octozi-raises-3m-to-deploy-agentic-ai-in-clinical-trial-data-operations-demonstrates-six-fold-throughput-gains 2026-05-28T22:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/secretome-therapeutics-secures-30-million-series-a-to-advance-cardiac-cell-therapy-for-duchenne-muscular-dystrophy 2026-05-28T22:08:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/secretome-therapeutics-secures-30-million-series-a-to-advance-cardiac-cell-therapy-for-duchenne-muscular-dystrophy 2026-05-28T22:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/aimedbio-invests-1-5-million-in-galaxy-for-ai-designed-brain-penetrating-antibody-development 2026-05-28T22:07:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aimedbio-invests-1-5-million-in-galaxy-for-ai-designed-brain-penetrating-antibody-development 2026-05-28T22:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/pet-imaging-in-alzheimer-disease-from-early-diagnosis-to-therapeutic-monitoring 2026-05-28T20:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pet-imaging-in-alzheimer-disease-from-early-diagnosis-to-therapeutic-monitoring 2026-05-28T20:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/south-africa-s-afrigen-biologics-becomes-first-african-facility-to-receive-gmp-certification-for-mrna-manufacturing 2026-05-28T20:26:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-africa-s-afrigen-biologics-becomes-first-african-facility-to-receive-gmp-certification-for-mrna-manufacturing 2026-05-28T20:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/gene-solutions-receives-fda-breakthrough-device-designation-for-spot-mas-10-multi-cancer-blood-test 2026-05-28T20:24:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-solutions-receives-fda-breakthrough-device-designation-for-spot-mas-10-multi-cancer-blood-test 2026-05-28T20:24:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-three-breakthrough-breast-cancer-treatments-for-earlier-stage-disease 2026-05-28T20:23:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-three-breakthrough-breast-cancer-treatments-for-earlier-stage-disease 2026-05-28T20:23:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pivekimab-sunirine-as-first-adc-for-ultra-rare-blood-cancer-bpdcn 2026-05-28T20:23:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pivekimab-sunirine-as-first-adc-for-ultra-rare-blood-cancer-bpdcn 2026-05-28T20:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-nejm-trial-provides-first-randomized-evidence-for-chiari-malformation-surgical-treatment 2026-05-28T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-nejm-trial-provides-first-randomized-evidence-for-chiari-malformation-surgical-treatment 2026-05-28T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-review-raises-substantial-concern-that-vaping-may-increase-cancer-risk-over-time 2026-05-28T20:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-review-raises-substantial-concern-that-vaping-may-increase-cancer-risk-over-time 2026-05-28T20:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-receives-ce-mark-for-first-dual-glucose-ketone-sensor-to-prevent-diabetic-ketoacidosis 2026-05-28T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-receives-ce-mark-for-first-dual-glucose-ketone-sensor-to-prevent-diabetic-ketoacidosis 2026-05-28T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/rectify-pharmaceuticals-reports-promising-preclinical-data-for-rty-406-in-primary-sclerosing-cholangitis-at-easl-2026 2026-05-28T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rectify-pharmaceuticals-reports-promising-preclinical-data-for-rty-406-in-primary-sclerosing-cholangitis-at-easl-2026 2026-05-28T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/viromissile-s-idov-safe-shows-30-46-response-rate-in-treatment-resistant-colorectal-cancer 2026-05-28T17:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viromissile-s-idov-safe-shows-30-46-response-rate-in-treatment-resistant-colorectal-cancer 2026-05-28T17:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-partners-with-colombia-on-260-million-vaccine-manufacturing-initiative 2026-05-28T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-partners-with-colombia-on-260-million-vaccine-manufacturing-initiative 2026-05-28T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/verge-genomics-rebrands-as-verge-labs-following-als-drug-trial-failure-pivots-to-ai-driven-target-discovery 2026-05-28T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verge-genomics-rebrands-as-verge-labs-following-als-drug-trial-failure-pivots-to-ai-driven-target-discovery 2026-05-28T17:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/solu-therapeutics-receives-fda-fast-track-designation-for-stx-0712-in-chronic-myelomonocytic-leukemia 2026-05-28T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solu-therapeutics-receives-fda-fast-track-designation-for-stx-0712-in-chronic-myelomonocytic-leukemia 2026-05-28T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/nielsen-biosciences-candin-achieves-primary-endpoint-in-first-phase-3-trial-for-common-warts-treatment 2026-05-28T16:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nielsen-biosciences-candin-achieves-primary-endpoint-in-first-phase-3-trial-for-common-warts-treatment 2026-05-28T16:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/indupro-doses-first-patient-in-phase-1-trial-of-proximity-based-bispecific-adc-idp-001-closes-77m-series-b 2026-05-28T16:12:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indupro-doses-first-patient-in-phase-1-trial-of-proximity-based-bispecific-adc-idp-001-closes-77m-series-b 2026-05-28T16:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/eom-pharmaceuticals-receives-fda-clearance-for-phase-2a-cancer-cachexia-trial-of-eom613 2026-05-28T16:11:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eom-pharmaceuticals-receives-fda-clearance-for-phase-2a-cancer-cachexia-trial-of-eom613 2026-05-28T16:11:05+00:00 hourly 0.9 https://trial.medpath.com/news/ember-lifesciences-secures-27m-series-a-funding-to-advance-cold-chain-technology-for-pharmaceutical-distribution 2026-05-28T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ember-lifesciences-secures-27m-series-a-funding-to-advance-cold-chain-technology-for-pharmaceutical-distribution 2026-05-28T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-inflammatory-therapy-thn391-for-diabetic-macular-edema 2026-05-28T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therini-bio-initiates-phase-1b-trial-of-novel-anti-inflammatory-therapy-thn391-for-diabetic-macular-edema 2026-05-28T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/aim-immunotech-positions-ampligen-as-potential-ebola-treatment-following-who-emergency-declaration 2026-05-28T16:09:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aim-immunotech-positions-ampligen-as-potential-ebola-treatment-following-who-emergency-declaration 2026-05-28T16:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/subtle-medical-receives-fda-clearance-for-subtlehd-pet-next-generation-ai-powered-image-acceleration-and-enhancement-software 2026-05-28T16:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subtle-medical-receives-fda-clearance-for-subtlehd-pet-next-generation-ai-powered-image-acceleration-and-enhancement-software 2026-05-28T16:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/natera-s-signatera-becomes-first-pmda-approved-mrd-test-in-japan-for-colorectal-cancer 2026-05-28T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-s-signatera-becomes-first-pmda-approved-mrd-test-in-japan-for-colorectal-cancer 2026-05-28T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-following-successful-phase-1a-results-in-metastatic-cancer 2026-05-28T16:07:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcode-therapeutics-advances-ttx-mc138-to-phase-2a-trial-following-successful-phase-1a-results-in-metastatic-cancer 2026-05-28T16:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/premia-and-lind-launch-joint-venture-to-transform-clinical-trial-enrollment-in-asia-pacific-with-ai-technology 2026-05-28T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/premia-and-lind-launch-joint-venture-to-transform-clinical-trial-enrollment-in-asia-pacific-with-ai-technology 2026-05-28T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-linzess-for-functional-constipation-in-children-as-young-as-2-years-old 2026-05-28T16:07:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-linzess-for-functional-constipation-in-children-as-young-as-2-years-old 2026-05-28T16:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-cardiac-monitoring-devices-market-to-reach-10-3-billion-by-2036-driven-by-rising-cardiovascular-disease-burden 2026-05-28T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-cardiac-monitoring-devices-market-to-reach-10-3-billion-by-2036-driven-by-rising-cardiovascular-disease-burden 2026-05-28T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/fare-launches-10-million-mind-meld-team-grant-program-to-accelerate-translational-food-allergy-research 2026-05-28T14:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fare-launches-10-million-mind-meld-team-grant-program-to-accelerate-translational-food-allergy-research 2026-05-28T14:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/atea-pharmaceuticals-advances-antiviral-pipeline-with-promising-drug-drug-interaction-data-and-first-in-class-hev-candidate 2026-05-28T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atea-pharmaceuticals-advances-antiviral-pipeline-with-promising-drug-drug-interaction-data-and-first-in-class-hev-candidate 2026-05-28T14:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-reports-positive-phase-1-data-for-tnx-1500-anti-cd40l-antibody-in-transplant-rejection-prevention 2026-05-28T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-reports-positive-phase-1-data-for-tnx-1500-anti-cd40l-antibody-in-transplant-rejection-prevention 2026-05-28T14:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/reprogram-biosciences-raises-6m-to-advance-mrna-tumor-cell-reprogramming-platform 2026-05-28T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reprogram-biosciences-raises-6m-to-advance-mrna-tumor-cell-reprogramming-platform 2026-05-28T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-comprehensive-liver-disease-panel-to-transform-chronic-liver-disease-management 2026-05-28T14:07:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-comprehensive-liver-disease-panel-to-transform-chronic-liver-disease-management 2026-05-28T14:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/tata-sons-backed-medtherapy-establishes-india-manufacturing-hub-for-car-t-cell-and-gene-therapies 2026-05-28T14:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tata-sons-backed-medtherapy-establishes-india-manufacturing-hub-for-car-t-cell-and-gene-therapies 2026-05-28T14:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/lifearc-partners-with-elpida-therapeutics-to-advance-gene-therapies-for-ultra-rare-pediatric-neurodegenerative-diseases 2026-05-28T14:07:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifearc-partners-with-elpida-therapeutics-to-advance-gene-therapies-for-ultra-rare-pediatric-neurodegenerative-diseases 2026-05-28T14:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/umecrine-cognition-secures-sek-67-million-to-complete-phase-1b-2a-trial-of-golexanolone-for-pbc-related-fatigue 2026-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umecrine-cognition-secures-sek-67-million-to-complete-phase-1b-2a-trial-of-golexanolone-for-pbc-related-fatigue 2026-05-28T14:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/medicinova-completes-phase-2-trial-of-tipelukast-for-nafld-and-hypertriglyceridemia-in-type-2-diabetes 2026-05-28T13:09:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicinova-completes-phase-2-trial-of-tipelukast-for-nafld-and-hypertriglyceridemia-in-type-2-diabetes 2026-05-28T13:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/noxopharm-s-sofra-platform-shows-200-fold-immune-activation-boost-in-cancer-research 2026-05-28T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noxopharm-s-sofra-platform-shows-200-fold-immune-activation-boost-in-cancer-research 2026-05-28T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/acurex-biosciences-awarded-asap-grant-to-advance-15-lo-targeting-approach-for-parkinson-s-disease 2026-05-28T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acurex-biosciences-awarded-asap-grant-to-advance-15-lo-targeting-approach-for-parkinson-s-disease 2026-05-28T13:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/imagion-biosystems-receives-fda-clearance-for-her2-targeted-mri-imaging-agent-trial 2026-05-28T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imagion-biosystems-receives-fda-clearance-for-her2-targeted-mri-imaging-agent-trial 2026-05-28T11:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/the-next-era-of-biomanufacturing-will-be-won-by-intelligence-not-size 2026-05-28T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-next-era-of-biomanufacturing-will-be-won-by-intelligence-not-size 2026-05-28T11:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-combinations-show-dramatic-survival-gains-in-mesothelioma-patients 2026-05-28T09:59:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-combinations-show-dramatic-survival-gains-in-mesothelioma-patients 2026-05-28T09:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/kardigan-files-for-ipo-with-three-late-stage-cardiovascular-programs-targeting-unmet-medical-needs 2026-05-28T09:59:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kardigan-files-for-ipo-with-three-late-stage-cardiovascular-programs-targeting-unmet-medical-needs 2026-05-28T09:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/biomunex-partners-with-ai-companies-to-accelerate-bispecific-antibody-discovery-in-cancer-immunotherapy 2026-05-28T07:10:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomunex-partners-with-ai-companies-to-accelerate-bispecific-antibody-discovery-in-cancer-immunotherapy 2026-05-28T07:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/depuy-synthes-secures-exclusive-distribution-rights-for-cgbio-s-growth-factor-bone-graft-substitute-novosis 2026-05-28T07:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/depuy-synthes-secures-exclusive-distribution-rights-for-cgbio-s-growth-factor-bone-graft-substitute-novosis 2026-05-28T07:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/systemic-gene-therapy-syncav1-shields-brain-from-tdp-43-damage-by-fortifying-neuronal-resilience 2026-05-28T07:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/systemic-gene-therapy-syncav1-shields-brain-from-tdp-43-damage-by-fortifying-neuronal-resilience 2026-05-28T07:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/acrivon-therapeutics-reports-44-response-rate-for-chk1-2-inhibitor-acr-368-in-endometrial-cancer-phase-ii-trial 2026-05-28T07:06:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrivon-therapeutics-reports-44-response-rate-for-chk1-2-inhibitor-acr-368-in-endometrial-cancer-phase-ii-trial 2026-05-28T07:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/b-well-connected-health-and-mytomorrows-partner-to-revolutionize-clinical-trial-patient-recruitment-through-ai-powered-data-integration 2026-05-28T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-well-connected-health-and-mytomorrows-partner-to-revolutionize-clinical-trial-patient-recruitment-through-ai-powered-data-integration 2026-05-28T07:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-d-analog-paricalcitol-shows-promise-in-pancreatic-cancer-trial-by-reprogramming-tumor-microenvironment 2026-05-28T07:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitamin-d-analog-paricalcitol-shows-promise-in-pancreatic-cancer-trial-by-reprogramming-tumor-microenvironment 2026-05-28T07:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/tga-expands-prescriber-access-for-psychedelic-assisted-therapy-boosting-emyria-s-clinical-network 2026-05-28T06:11:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tga-expands-prescriber-access-for-psychedelic-assisted-therapy-boosting-emyria-s-clinical-network 2026-05-28T06:11:30+00:00 hourly 0.9 https://trial.medpath.com/news/nodthera-s-nlrp3-inhibitor-ruvonoflast-shows-promising-anti-inflammatory-effects-in-cardiovascular-risk-patients 2026-05-28T05:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nodthera-s-nlrp3-inhibitor-ruvonoflast-shows-promising-anti-inflammatory-effects-in-cardiovascular-risk-patients 2026-05-28T05:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/ionetix-receives-first-anda-approval-for-gallium-ga-68-gozetotide-psma-pet-imaging-agent 2026-05-28T05:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionetix-receives-first-anda-approval-for-gallium-ga-68-gozetotide-psma-pet-imaging-agent 2026-05-28T05:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/autobahn-therapeutics-receives-fda-fast-track-designation-for-elunetirom-in-bipolar-depression 2026-05-28T05:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autobahn-therapeutics-receives-fda-fast-track-designation-for-elunetirom-in-bipolar-depression 2026-05-28T05:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/consano-bio-receives-fda-ind-clearance-for-c-1101-a-first-in-class-non-opioid-biologic-for-chronic-sciatica 2026-05-28T05:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consano-bio-receives-fda-ind-clearance-for-c-1101-a-first-in-class-non-opioid-biologic-for-chronic-sciatica 2026-05-28T05:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/hologic-s-breast-cancer-index-test-demonstrates-significant-impact-on-extended-endocrine-therapy-decisions-in-real-world-study 2026-05-28T05:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hologic-s-breast-cancer-index-test-demonstrates-significant-impact-on-extended-endocrine-therapy-decisions-in-real-world-study 2026-05-28T05:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/delphia-therapeutics-appoints-david-kerstein-as-cmo-to-advance-novel-activation-lethality-cancer-platform 2026-05-28T05:49:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delphia-therapeutics-appoints-david-kerstein-as-cmo-to-advance-novel-activation-lethality-cancer-platform 2026-05-28T05:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-reports-durable-responses-with-unloxcyt-in-advanced-skin-cancer-at-asco-2026 2026-05-28T05:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-reports-durable-responses-with-unloxcyt-in-advanced-skin-cancer-at-asco-2026 2026-05-28T05:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/new-proposal-signals-major-reforms-to-the-340b-drug-discount-program 2026-05-28T05:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-proposal-signals-major-reforms-to-the-340b-drug-discount-program 2026-05-28T05:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-invests-3-83-billion-in-vaccine-platform-through-three-strategic-acquisitions 2026-05-28T03:07:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-invests-3-83-billion-in-vaccine-platform-through-three-strategic-acquisitions 2026-05-28T03:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/former-palantir-executives-launch-perceptic-with-12m-to-unify-ai-driven-drug-discovery-platform 2026-05-28T03:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-palantir-executives-launch-perceptic-with-12m-to-unify-ai-driven-drug-discovery-platform 2026-05-28T03:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/bayescna-lowers-cancer-dna-detection-threshold-to-5-enabling-non-invasive-tumor-monitoring 2026-05-27T23:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayescna-lowers-cancer-dna-detection-threshold-to-5-enabling-non-invasive-tumor-monitoring 2026-05-27T23:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/dapagliflozin-reduces-heart-failure-risk-by-82-in-carriers-of-cardiomyopathy-genetic-variants 2026-05-27T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dapagliflozin-reduces-heart-failure-risk-by-82-in-carriers-of-cardiomyopathy-genetic-variants 2026-05-27T19:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/hyperfine-s-portable-mri-system-reduces-emergency-department-imaging-wait-times-by-over-6-hours-in-clinical-trial 2026-05-27T18:08:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hyperfine-s-portable-mri-system-reduces-emergency-department-imaging-wait-times-by-over-6-hours-in-clinical-trial 2026-05-27T18:08:49+00:00 hourly 0.9 https://trial.medpath.com/news/rogaratinib-achieves-41-7-response-rate-in-sdh-deficient-gist-demonstrating-breakthrough-efficacy-for-previously-untreatable-tumor-subtype 2026-05-27T18:08:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rogaratinib-achieves-41-7-response-rate-in-sdh-deficient-gist-demonstrating-breakthrough-efficacy-for-previously-untreatable-tumor-subtype 2026-05-27T18:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-opakalim-shows-promise-in-epilepsy-trials-with-superior-tolerability-profile 2026-05-27T18:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-opakalim-shows-promise-in-epilepsy-trials-with-superior-tolerability-profile 2026-05-27T18:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/kazia-therapeutics-triples-enrollment-in-phase-1b-trial-of-paxalisib-for-advanced-triple-negative-breast-cancer 2026-05-27T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazia-therapeutics-triples-enrollment-in-phase-1b-trial-of-paxalisib-for-advanced-triple-negative-breast-cancer 2026-05-27T18:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/lucis-secures-20-million-series-a-to-scale-ai-powered-preventive-health-platform-across-europe 2026-05-27T18:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lucis-secures-20-million-series-a-to-scale-ai-powered-preventive-health-platform-across-europe 2026-05-27T18:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/neurovalens-receives-fda-de-novo-approval-for-ptsd-treatment-device-modius-spero 2026-05-27T18:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurovalens-receives-fda-de-novo-approval-for-ptsd-treatment-device-modius-spero 2026-05-27T18:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-shifts-policy-americans-with-ebola-at-kenya-facility-may-be-treated-in-the-united-states 2026-05-27T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-shifts-policy-americans-with-ebola-at-kenya-facility-may-be-treated-in-the-united-states 2026-05-27T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-drug-like-molecules-that-directly-target-b-arrestins-discovered-opening-new-path-for-gpcr-targeted-therapies 2026-05-27T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-drug-like-molecules-that-directly-target-b-arrestins-discovered-opening-new-path-for-gpcr-targeted-therapies 2026-05-27T17:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-emerges-as-a-powerful-ally-in-the-fight-against-als-12-years-after-the-ice-bucket-challenge 2026-05-27T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-emerges-as-a-powerful-ally-in-the-fight-against-als-12-years-after-the-ice-bucket-challenge 2026-05-27T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/merz-therapeutics-partners-with-kvvit-to-bring-inbrija-parkinson-s-treatment-to-greater-china 2026-05-27T11:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merz-therapeutics-partners-with-kvvit-to-bring-inbrija-parkinson-s-treatment-to-greater-china 2026-05-27T11:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/bial-completes-phase-2b-activate-study-of-potential-first-in-class-gba1-parkinson-s-treatment 2026-05-27T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bial-completes-phase-2b-activate-study-of-potential-first-in-class-gba1-parkinson-s-treatment 2026-05-27T11:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-partners-with-teikoku-seiyaku-for-novel-rhmmp-7-therapy-manufacturing-to-treat-lumbar-disc-herniation 2026-05-27T11:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-partners-with-teikoku-seiyaku-for-novel-rhmmp-7-therapy-manufacturing-to-treat-lumbar-disc-herniation 2026-05-27T11:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/wearable-devices-reveal-sleep-duration-linked-to-menstrual-cycle-regularity-large-scale-study-shows 2026-05-27T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wearable-devices-reveal-sleep-duration-linked-to-menstrual-cycle-regularity-large-scale-study-shows 2026-05-27T07:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/cloudbreak-b-receives-fda-clearance-for-cbt-199-ophthalmic-drug-trial-and-submits-ind-for-dry-eye-candidate-cbt-358 2026-05-27T01:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cloudbreak-b-receives-fda-clearance-for-cbt-199-ophthalmic-drug-trial-and-submits-ind-for-dry-eye-candidate-cbt-358 2026-05-27T01:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/entheon-biomedical-terminates-business-combination-with-nutravisor-receives-cad-350000-settlement 2026-05-27T00:06:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entheon-biomedical-terminates-business-combination-with-nutravisor-receives-cad-350000-settlement 2026-05-27T00:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-class-3-1-classical-formula-drug-zhenwu-tang-granules-marking-tcm-modernization-milestone 2026-05-27T00:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-class-3-1-classical-formula-drug-zhenwu-tang-granules-marking-tcm-modernization-milestone 2026-05-27T00:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsy-reshapes-early-cancer-management-from-mrd-detection-to-cancer-interception 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquid-biopsy-reshapes-early-cancer-management-from-mrd-detection-to-cancer-interception 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-tumor-microenvironment-as-a-driver-of-disease-progression-and-therapeutic-response-in-gynecological-malignancies 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-tumor-microenvironment-as-a-driver-of-disease-progression-and-therapeutic-response-in-gynecological-malignancies 2026-05-26T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/quanterix-grants-336804-rsus-to-three-new-employees-under-nasdaq-inducement-rule 2026-05-26T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quanterix-grants-336804-rsus-to-three-new-employees-under-nasdaq-inducement-rule 2026-05-26T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/lung-cancer-is-no-longer-just-a-smoker-s-disease-the-case-for-broader-awareness-and-earlier-detection 2026-05-26T18:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-cancer-is-no-longer-just-a-smoker-s-disease-the-case-for-broader-awareness-and-earlier-detection 2026-05-26T18:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/short-term-fasting-around-chemotherapy-improves-response-and-pfs-in-advanced-ovarian-cancer-pilot-trial 2026-05-26T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/short-term-fasting-around-chemotherapy-improves-response-and-pfs-in-advanced-ovarian-cancer-pilot-trial 2026-05-26T11:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/four-year-match-trial-data-shows-70-transplant-free-survival-with-regenerative-macrophage-therapy-in-liver-cirrhosis 2026-05-26T06:20:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/four-year-match-trial-data-shows-70-transplant-free-survival-with-regenerative-macrophage-therapy-in-liver-cirrhosis 2026-05-26T06:20:07+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-approval-for-ranibizumab-biosimilar-vislyfa-expanding-european-treatment-options-for-retinal-diseases 2026-05-26T06:18:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-approval-for-ranibizumab-biosimilar-vislyfa-expanding-european-treatment-options-for-retinal-diseases 2026-05-26T06:18:57+00:00 hourly 0.9 https://trial.medpath.com/news/macrophage-cell-therapy-shows-70-transplant-free-survival-rate-in-advanced-liver-disease-trial 2026-05-26T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrophage-cell-therapy-shows-70-transplant-free-survival-rate-in-advanced-liver-disease-trial 2026-05-26T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-biosciences-achieves-30-higher-efficacy-than-champix-in-biomarker-positive-smoking-cessation-population 2026-05-26T06:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-biosciences-achieves-30-higher-efficacy-than-champix-in-biomarker-positive-smoking-cessation-population 2026-05-26T06:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/ugandan-biotech-company-files-us-patent-for-multi-strain-ebola-mrna-vaccine-platform 2026-05-26T06:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ugandan-biotech-company-files-us-patent-for-multi-strain-ebola-mrna-vaccine-platform 2026-05-26T06:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-b-mil62-shows-93-1-relapse-risk-reduction-in-phase-3-trial-for-aqp4-igg-nmosd 2026-05-26T06:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obinutuzumab-b-mil62-shows-93-1-relapse-risk-reduction-in-phase-3-trial-for-aqp4-igg-nmosd 2026-05-26T06:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-s-cardiamp-cell-therapy-shows-sustained-exercise-improvements-in-refractory-angina-patients 2026-05-26T06:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-s-cardiamp-cell-therapy-shows-sustained-exercise-improvements-in-refractory-angina-patients 2026-05-26T06:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-comprehensive-oncology-data-at-asco-2026-featuring-elacestrant-combination-studies 2026-05-26T06:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menarini-group-to-present-comprehensive-oncology-data-at-asco-2026-featuring-elacestrant-combination-studies 2026-05-26T06:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-datroway-as-first-trop2-directed-adc-for-first-line-triple-negative-breast-cancer-treatment 2026-05-26T06:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-datroway-as-first-trop2-directed-adc-for-first-line-triple-negative-breast-cancer-treatment 2026-05-26T06:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-recommends-discontinuation-of-crizanlizumab-following-failed-efficacy-trial 2026-05-26T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-drug-regulator-recommends-discontinuation-of-crizanlizumab-following-failed-efficacy-trial 2026-05-26T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/treefrog-therapeutics-tfg-001-shows-rapid-dopamine-release-and-enhanced-reinnervation-in-parkinson-s-disease-models 2026-05-26T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treefrog-therapeutics-tfg-001-shows-rapid-dopamine-release-and-enhanced-reinnervation-in-parkinson-s-disease-models 2026-05-26T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/strainx-bioworks-raises-13-million-to-scale-precision-fermentation-platform-for-alternative-protein-production 2026-05-26T06:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strainx-bioworks-raises-13-million-to-scale-precision-fermentation-platform-for-alternative-protein-production 2026-05-26T06:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-expands-precision-oncology-portfolio-with-new-cancer-test-launches-amid-steady-diagnostics-demand 2026-05-26T06:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-expands-precision-oncology-portfolio-with-new-cancer-test-launches-amid-steady-diagnostics-demand 2026-05-26T06:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/calibrating-microglia-states-in-alzheimer-s-disease-from-anti-amyloid-antibodies-to-multi-target-microenvironment-protection 2026-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calibrating-microglia-states-in-alzheimer-s-disease-from-anti-amyloid-antibodies-to-multi-target-microenvironment-protection 2026-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-expands-oncology-reach-with-zydus-lifesciences-partnership-for-gcc-markets 2026-05-24T14:46:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sakar-healthcare-expands-oncology-reach-with-zydus-lifesciences-partnership-for-gcc-markets 2026-05-24T14:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/semnur-pharmaceuticals-secures-100-million-strategic-investment-from-iholding-group-to-advance-non-opioid-pain-therapy-semdexa 2026-05-24T14:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semnur-pharmaceuticals-secures-100-million-strategic-investment-from-iholding-group-to-advance-non-opioid-pain-therapy-semdexa 2026-05-24T14:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-low-dose-immunotherapy-combination-demonstrates-superior-survival-in-metastatic-head-and-neck-cancer 2026-05-24T14:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-low-dose-immunotherapy-combination-demonstrates-superior-survival-in-metastatic-head-and-neck-cancer 2026-05-24T14:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/fulgent-genetics-reports-60-response-rate-for-fid-007-in-head-and-neck-cancer-phase-2-trial 2026-05-24T14:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulgent-genetics-reports-60-response-rate-for-fid-007-in-head-and-neck-cancer-phase-2-trial 2026-05-24T14:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-levothyroxine-sodium-tablets-in-1-87-billion-market 2026-05-24T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-levothyroxine-sodium-tablets-in-1-87-billion-market 2026-05-24T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-alastin-regenerative-skincare-brand-across-japan-and-asia-pacific-markets 2026-05-24T14:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-launches-alastin-regenerative-skincare-brand-across-japan-and-asia-pacific-markets 2026-05-24T14:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-secures-first-global-approval-for-plerixafor-in-saudi-arabia 2026-05-24T14:00:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-remedies-secures-first-global-approval-for-plerixafor-in-saudi-arabia 2026-05-24T14:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-mrna-vaccine-shows-promise-against-three-ebola-virus-strains-in-preclinical-studies 2026-05-24T13:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-mrna-vaccine-shows-promise-against-three-ebola-virus-strains-in-preclinical-studies 2026-05-24T13:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/akari-reports-breakthrough-preclinical-data-for-aktx-101-in-kras-mutated-pancreatic-cancer-stock-surges-50 2026-05-24T13:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-reports-breakthrough-preclinical-data-for-aktx-101-in-kras-mutated-pancreatic-cancer-stock-surges-50 2026-05-24T13:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/bundibugyo-ebola-outbreak-in-drc-and-uganda-declared-public-health-emergency-of-international-concern 2026-05-24T13:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bundibugyo-ebola-outbreak-in-drc-and-uganda-declared-public-health-emergency-of-international-concern 2026-05-24T13:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-hepatitis-delta-treatment-with-gilead-s-hepcludex 2026-05-24T13:44:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-approval-for-hepatitis-delta-treatment-with-gilead-s-hepcludex 2026-05-24T13:44:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-prescription-to-otc-switch-for-adapalene-benzoyl-peroxide-acne-gel 2026-05-24T13:41:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-prescription-to-otc-switch-for-adapalene-benzoyl-peroxide-acne-gel 2026-05-24T13:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-approval-for-vijoice-first-treatment-for-rare-pik3ca-related-overgrowth-disorders 2026-05-22T19:17:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-conditional-approval-for-vijoice-first-treatment-for-rare-pik3ca-related-overgrowth-disorders 2026-05-22T19:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/vitrafy-s-no-wash-frozen-platelet-technology-achieves-94-recovery-rate-in-us-army-validation-study 2026-05-22T19:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitrafy-s-no-wash-frozen-platelet-technology-achieves-94-recovery-rate-in-us-army-validation-study 2026-05-22T19:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-accelerates-velzatinib-phase-iii-trial-following-promising-first-line-gist-results 2026-05-22T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-accelerates-velzatinib-phase-iii-trial-following-promising-first-line-gist-results 2026-05-22T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-foundationone-cdx-as-companion-diagnostic-for-tepotinib-in-met-exon-14-positive-nsclc 2026-05-22T19:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-foundationone-cdx-as-companion-diagnostic-for-tepotinib-in-met-exon-14-positive-nsclc 2026-05-22T19:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-s-astegolimab-copd-program-highlights-critical-trial-design-flaws-in-phase-3-confirmatory-studies 2026-05-22T18:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-s-astegolimab-copd-program-highlights-critical-trial-design-flaws-in-phase-3-confirmatory-studies 2026-05-22T18:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/lupeng-pharmaceutical-s-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-r-r-mcl-global-phase-3-rocket-cll-trial-underway 2026-05-22T18:55:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupeng-pharmaceutical-s-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-r-r-mcl-global-phase-3-rocket-cll-trial-underway 2026-05-22T18:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-hiv-therapy-ahead-of-schedule 2026-05-22T18:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-hiv-therapy-ahead-of-schedule 2026-05-22T18:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/nuance-pharma-receives-nmpa-clearance-for-actair-r-phase-iii-trial-in-china 2026-05-22T18:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuance-pharma-receives-nmpa-clearance-for-actair-r-phase-iii-trial-in-china 2026-05-22T18:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-partners-with-beyond-drug-development-to-advance-novel-mri-based-cancer-imaging-technology 2026-05-22T18:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trivarx-partners-with-beyond-drug-development-to-advance-novel-mri-based-cancer-imaging-technology 2026-05-22T18:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/858-therapeutics-parg-inhibitor-etx-19477-shows-57-orr-in-brca-mutated-ovarian-and-breast-cancer-earns-fda-fast-track-designation 2026-05-22T18:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/858-therapeutics-parg-inhibitor-etx-19477-shows-57-orr-in-brca-mutated-ovarian-and-breast-cancer-earns-fda-fast-track-designation 2026-05-22T18:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-targets-q2-2027-launch-for-mint-patch-pump-to-challenge-insulet-s-market-dominance 2026-05-22T18:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-bionics-targets-q2-2027-launch-for-mint-patch-pump-to-challenge-insulet-s-market-dominance 2026-05-22T18:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-structured-yoga-program-significantly-reduces-mood-disturbance-anxiety-fatigue-and-insomnia-in-cancer-survivors 2026-05-22T18:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-structured-yoga-program-significantly-reduces-mood-disturbance-anxiety-fatigue-and-insomnia-in-cancer-survivors 2026-05-22T18:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-and-abbvie-dose-first-patient-in-phase-iib-iii-naavigate-trial-of-one-time-gene-therapy-sura-vec-for-diabetic-retinopathy 2026-05-22T18:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-and-abbvie-dose-first-patient-in-phase-iib-iii-naavigate-trial-of-one-time-gene-therapy-sura-vec-for-diabetic-retinopathy 2026-05-22T18:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/ingenia-therapeutics-receives-krx-approval-for-ipo-as-tie2-targeted-therapies-advance-to-phase-3 2026-05-22T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenia-therapeutics-receives-krx-approval-for-ipo-as-tie2-targeted-therapies-advance-to-phase-3 2026-05-22T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/servier-to-present-long-term-voranigo-data-and-novel-adc-results-at-asco-2026 2026-05-22T18:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-to-present-long-term-voranigo-data-and-novel-adc-results-at-asco-2026 2026-05-22T18:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-and-verdinexor-combination-therapy-enters-canine-trial-for-pediatric-brain-cancer-treatment 2026-05-22T18:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-and-verdinexor-combination-therapy-enters-canine-trial-for-pediatric-brain-cancer-treatment 2026-05-22T18:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-q1-2026-revenue-growth-driven-by-iqirvo-royalties-advances-pipeline-across-liver-disease-portfolio 2026-05-22T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-reports-strong-q1-2026-revenue-growth-driven-by-iqirvo-royalties-advances-pipeline-across-liver-disease-portfolio 2026-05-22T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/manchester-biotech-imperagen-raises-ps5m-to-advance-quantum-ai-enzyme-engineering-platform 2026-05-22T18:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manchester-biotech-imperagen-raises-ps5m-to-advance-quantum-ai-enzyme-engineering-platform 2026-05-22T18:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-car-t-therapy-faces-persistent-logistical-barriers-in-large-b-cell-lymphoma-treatment 2026-05-22T18:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-car-t-therapy-faces-persistent-logistical-barriers-in-large-b-cell-lymphoma-treatment 2026-05-22T18:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-two-major-clinical-programs-in-critical-care-and-cardiovascular-disease 2026-05-22T18:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-advances-two-major-clinical-programs-in-critical-care-and-cardiovascular-disease 2026-05-22T18:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/daraxonrasib-doubles-overall-survival-in-metastatic-pancreatic-cancer-highlighted-at-asco-2025 2026-05-22T18:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daraxonrasib-doubles-overall-survival-in-metastatic-pancreatic-cancer-highlighted-at-asco-2025 2026-05-22T18:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/oddifact-secures-european-orphan-drug-designation-for-infliximab-in-kawasaki-disease 2026-05-22T18:12:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oddifact-secures-european-orphan-drug-designation-for-infliximab-in-kawasaki-disease 2026-05-22T18:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/outcomes4me-acquires-ai-powered-platforms-to-enhance-cancer-patient-access-to-clinical-trials 2026-05-22T18:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outcomes4me-acquires-ai-powered-platforms-to-enhance-cancer-patient-access-to-clinical-trials 2026-05-22T18:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/massive-bio-and-beekeeperai-deploy-privacy-preserving-ai-to-expand-cancer-trial-access-in-underserved-communities 2026-05-22T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-bio-and-beekeeperai-deploy-privacy-preserving-ai-to-expand-cancer-trial-access-in-underserved-communities 2026-05-22T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/grundium-acquires-visiopharm-to-create-integrated-ai-driven-precision-pathology-platform 2026-05-22T18:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grundium-acquires-visiopharm-to-create-integrated-ai-driven-precision-pathology-platform 2026-05-22T18:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-to-acquire-innocsai-in-320-million-deal-gaining-next-generation-car-t-pipeline-for-hematologic-and-solid-tumors 2026-05-22T18:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-to-acquire-innocsai-in-320-million-deal-gaining-next-generation-car-t-pipeline-for-hematologic-and-solid-tumors 2026-05-22T18:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/amr-bio-launches-with-phase-iii-ready-antimicrobial-xf-73-to-combat-post-surgical-infections 2026-05-22T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amr-bio-launches-with-phase-iii-ready-antimicrobial-xf-73-to-combat-post-surgical-infections 2026-05-22T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/remote-blood-sampling-technology-shows-promise-for-alzheimer-s-disease-biomarker-testing 2026-05-22T17:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-blood-sampling-technology-shows-promise-for-alzheimer-s-disease-biomarker-testing 2026-05-22T17:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/concept-life-sciences-and-openbench-launch-ai-driven-success-based-drug-discovery-partnership 2026-05-22T17:46:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-life-sciences-and-openbench-launch-ai-driven-success-based-drug-discovery-partnership 2026-05-22T17:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-sintilimab-fruquintinib-combination-for-advanced-renal-cell-carcinoma 2026-05-22T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-sintilimab-fruquintinib-combination-for-advanced-renal-cell-carcinoma 2026-05-22T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-acquires-spr-therapeutics-for-650m-to-expand-pain-management-portfolio 2026-05-22T17:43:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-acquires-spr-therapeutics-for-650m-to-expand-pain-management-portfolio 2026-05-22T17:43:38+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-reports-positive-phase-1-2-data-for-ozekibart-in-colorectal-cancer-plans-fda-filing-for-chondrosarcoma 2026-05-22T17:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-reports-positive-phase-1-2-data-for-ozekibart-in-colorectal-cancer-plans-fda-filing-for-chondrosarcoma 2026-05-22T17:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-fl118-for-osteosarcoma-treatment 2026-05-22T17:40:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-fl118-for-osteosarcoma-treatment 2026-05-22T17:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/grey-matters-takes-delivery-of-first-brain-dedicated-pet-scanner-for-novascan-neuroimaging-clinic-in-florida 2026-05-22T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grey-matters-takes-delivery-of-first-brain-dedicated-pet-scanner-for-novascan-neuroimaging-clinic-in-florida 2026-05-22T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/insphero-acquires-phenovista-biosciences-to-strengthen-3d-drug-testing-platform 2026-05-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insphero-acquires-phenovista-biosciences-to-strengthen-3d-drug-testing-platform 2026-05-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-achieves-first-clinical-proof-of-mrna-therapy-activity-in-primary-ciliary-dyskinesia 2026-05-22T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-achieves-first-clinical-proof-of-mrna-therapy-activity-in-primary-ciliary-dyskinesia 2026-05-22T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-advances-small-molecule-oncology-pipeline-with-european-investment-bank-financing-and-partnership-strategy 2026-05-22T17:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-advances-small-molecule-oncology-pipeline-with-european-investment-bank-financing-and-partnership-strategy 2026-05-22T17:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-edison-histotripsy-system-earns-taiwan-fda-approval-for-non-invasive-liver-tumor-treatment 2026-05-22T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histosonics-edison-histotripsy-system-earns-taiwan-fda-approval-for-non-invasive-liver-tumor-treatment 2026-05-22T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-faces-mixed-results-in-patent-challenges-against-genzyme-s-gene-therapy-analytical-methods 2026-05-22T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-faces-mixed-results-in-patent-challenges-against-genzyme-s-gene-therapy-analytical-methods 2026-05-22T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/ichnos-glenmark-innovation-unveils-first-in-class-multispecific-cancer-drug-isb-2301-for-solid-tumors 2026-05-22T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ichnos-glenmark-innovation-unveils-first-in-class-multispecific-cancer-drug-isb-2301-for-solid-tumors 2026-05-22T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/in-utero-gene-therapy-approaches-first-fda-trial-after-25-years-of-development 2026-05-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-utero-gene-therapy-approaches-first-fda-trial-after-25-years-of-development 2026-05-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-receives-fda-ind-clearance-for-qt-019c-universal-car-t-therapy-targeting-autoimmune-diseases 2026-05-22T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qihan-biotech-receives-fda-ind-clearance-for-qt-019c-universal-car-t-therapy-targeting-autoimmune-diseases 2026-05-22T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-to-develop-novel-regenerative-therapy-for-idiopathic-pulmonary-fibrosis 2026-05-22T17:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oorja-bio-launches-with-30m-to-develop-novel-regenerative-therapy-for-idiopathic-pulmonary-fibrosis 2026-05-22T17:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/23andme-partners-with-healthex-to-launch-ai-powered-health-summary-integrating-genetic-and-medical-data 2026-05-22T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/23andme-partners-with-healthex-to-launch-ai-powered-health-summary-integrating-genetic-and-medical-data 2026-05-22T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/flow-pharma-receives-patent-allowance-for-universal-ebola-treatment-using-siltuximab 2026-05-22T17:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flow-pharma-receives-patent-allowance-for-universal-ebola-treatment-using-siltuximab 2026-05-22T17:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-researchers-launch-largest-fmt-trial-to-enhance-lung-cancer-immunotherapy 2026-05-22T17:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-researchers-launch-largest-fmt-trial-to-enhance-lung-cancer-immunotherapy 2026-05-22T17:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-shows-promise-as-immunotherapy-for-treatment-resistant-depression-in-pilot-trial 2026-05-22T17:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tocilizumab-shows-promise-as-immunotherapy-for-treatment-resistant-depression-in-pilot-trial 2026-05-22T17:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-speech-assessment-detects-alzheimer-s-pathology-through-automated-phone-calls 2026-05-22T16:59:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-speech-assessment-detects-alzheimer-s-pathology-through-automated-phone-calls 2026-05-22T16:59:59+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-doses-first-patients-in-phase-1-trial-of-htx-001-for-cardiac-fibrosis 2026-05-22T16:59:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-doses-first-patients-in-phase-1-trial-of-htx-001-for-cardiac-fibrosis 2026-05-22T16:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/collaborative-drug-discovery-partners-with-eli-lilly-to-integrate-ai-ml-models-into-cdd-vault-platform 2026-05-22T16:56:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collaborative-drug-discovery-partners-with-eli-lilly-to-integrate-ai-ml-models-into-cdd-vault-platform 2026-05-22T16:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-initiates-first-in-human-trial-of-iontophoretic-drug-delivery-platform-for-pancreatic-cancer 2026-05-22T16:55:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-initiates-first-in-human-trial-of-iontophoretic-drug-delivery-platform-for-pancreatic-cancer 2026-05-22T16:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/sarah-cannon-research-institute-partners-with-pfizer-to-accelerate-community-based-oncology-trials 2026-05-22T16:52:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarah-cannon-research-institute-partners-with-pfizer-to-accelerate-community-based-oncology-trials 2026-05-22T16:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/from-dysbiosis-to-precision-medicine-targeting-the-microbial-metabolic-axis-in-ibd-management 2026-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-dysbiosis-to-precision-medicine-targeting-the-microbial-metabolic-axis-in-ibd-management 2026-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oura-files-confidentially-for-us-ipo-as-smart-ring-health-platform-targets-2-billion-revenue 2026-05-21T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oura-files-confidentially-for-us-ipo-as-smart-ring-health-platform-targets-2-billion-revenue 2026-05-21T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/surgeon-general-advisory-warns-excessive-screen-use-is-a-top-public-health-threat-for-children-and-adolescents 2026-05-21T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgeon-general-advisory-warns-excessive-screen-use-is-a-top-public-health-threat-for-children-and-adolescents 2026-05-21T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-first-in-class-gipr-antagonist-at7687-shows-promising-phase-1-results-and-preclinical-combination-data-at-ada-2026 2026-05-21T11:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antag-therapeutics-first-in-class-gipr-antagonist-at7687-shows-promising-phase-1-results-and-preclinical-combination-data-at-ada-2026 2026-05-21T11:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ayvakit-avapritinib-high-response-rates-in-rare-cancers-and-mastocytosis-with-critical-safety-monitoring-requirements 2026-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ayvakit-avapritinib-high-response-rates-in-rare-cancers-and-mastocytosis-with-critical-safety-monitoring-requirements 2026-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-biosciences-secures-pscc-boost-funding-to-develop-first-single-cell-assay-for-adc-therapies-in-oncology 2026-05-20T09:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-biosciences-secures-pscc-boost-funding-to-develop-first-single-cell-assay-for-adc-therapies-in-oncology 2026-05-20T09:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-dysport-shows-superior-duration-over-botox-in-first-head-to-head-spasticity-trial 2026-05-20T09:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-dysport-shows-superior-duration-over-botox-in-first-head-to-head-spasticity-trial 2026-05-20T09:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/matter-bio-files-first-ind-for-listeria-based-immunotherapy-targeting-pancreatic-cancer 2026-05-20T09:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matter-bio-files-first-ind-for-listeria-based-immunotherapy-targeting-pancreatic-cancer 2026-05-20T09:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/dynamx-bioadaptor-shows-88-reduction-in-cardiovascular-death-compared-to-drug-eluting-stents-in-four-year-trial 2026-05-20T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamx-bioadaptor-shows-88-reduction-in-cardiovascular-death-compared-to-drug-eluting-stents-in-four-year-trial 2026-05-20T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-advances-my006-peanut-allergy-treatment-to-phase-ib-following-positive-safety-data 2026-05-20T09:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabylon-advances-my006-peanut-allergy-treatment-to-phase-ib-following-positive-safety-data 2026-05-20T09:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-raises-5m-seed-round-as-ai-platform-achieves-97-accuracy-in-clinical-data-abstraction 2026-05-20T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-health-raises-5m-seed-round-as-ai-platform-achieves-97-accuracy-in-clinical-data-abstraction 2026-05-20T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-series-a-to-advance-novel-ipf-therapy-orj-001 2026-05-20T09:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oorja-bio-launches-with-30m-series-a-to-advance-novel-ipf-therapy-orj-001 2026-05-20T09:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-cellular-dynamics-opens-200-million-ipsc-manufacturing-facility-to-quadruple-production-capacity 2026-05-20T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-cellular-dynamics-opens-200-million-ipsc-manufacturing-facility-to-quadruple-production-capacity 2026-05-20T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-glaucoma-drug-pdp-716-receives-fda-complete-response-letter-due-to-manufacturing-facility-issues 2026-05-20T09:00:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-glaucoma-drug-pdp-716-receives-fda-complete-response-letter-due-to-manufacturing-facility-issues 2026-05-20T09:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/mentari-therapeutics-goes-public-through-421m-reverse-merger-to-advance-novel-pacap-targeting-migraine-therapies 2026-05-20T08:59:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mentari-therapeutics-goes-public-through-421m-reverse-merger-to-advance-novel-pacap-targeting-migraine-therapies 2026-05-20T08:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/risen-pharma-initiates-phase-2-trial-of-rp902-for-alzheimer-s-disease-in-china 2026-05-20T08:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risen-pharma-initiates-phase-2-trial-of-rp902-for-alzheimer-s-disease-in-china 2026-05-20T08:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/dropshot-therapeutics-advances-renal-disease-program-to-clinical-stage-using-etherna-s-mrna-platform 2026-05-20T08:53:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dropshot-therapeutics-advances-renal-disease-program-to-clinical-stage-using-etherna-s-mrna-platform 2026-05-20T08:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/blank-bio-secures-7-2m-seed-funding-and-pacbio-partnership-to-advance-rna-foundation-models-for-precision-oncology 2026-05-20T08:51:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blank-bio-secures-7-2m-seed-funding-and-pacbio-partnership-to-advance-rna-foundation-models-for-precision-oncology 2026-05-20T08:51:39+00:00 hourly 0.9 https://trial.medpath.com/news/mekanistic-therapeutics-receives-fda-clearance-for-first-in-class-dual-pi3k-egfr-inhibitor-mtx-531 2026-05-20T08:51:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mekanistic-therapeutics-receives-fda-clearance-for-first-in-class-dual-pi3k-egfr-inhibitor-mtx-531 2026-05-20T08:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/matisse-pharmaceuticals-receives-fda-ind-clearance-for-novel-sepsis-treatment-isupartob-sodium 2026-05-20T08:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matisse-pharmaceuticals-receives-fda-ind-clearance-for-novel-sepsis-treatment-isupartob-sodium 2026-05-20T08:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-partners-with-merck-for-phase-3-colorectal-cancer-trial-combining-zanzalintinib-with-keytruda 2026-05-20T08:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-partners-with-merck-for-phase-3-colorectal-cancer-trial-combining-zanzalintinib-with-keytruda 2026-05-20T08:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-for-ulcerative-colitis 2026-05-20T08:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-for-ulcerative-colitis 2026-05-20T08:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-to-bring-physics-grounded-drug-discovery-models-to-google-cloud-marketplace 2026-05-20T08:47:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandboxaq-to-bring-physics-grounded-drug-discovery-models-to-google-cloud-marketplace 2026-05-20T08:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/proencia-biotechnology-secures-pre-seed-funding-to-advance-novel-periodontal-disease-treatment-pipeline 2026-05-20T08:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proencia-biotechnology-secures-pre-seed-funding-to-advance-novel-periodontal-disease-treatment-pipeline 2026-05-20T08:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/cyclana-bio-launches-500-patient-study-to-decode-endometriosis-mechanisms-using-novel-tissue-based-approach 2026-05-20T08:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclana-bio-launches-500-patient-study-to-decode-endometriosis-mechanisms-using-novel-tissue-based-approach 2026-05-20T08:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/neurodiscovery-ai-launches-neuroterminal-platform-to-accelerate-neurological-clinical-trial-recruitment 2026-05-20T08:44:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurodiscovery-ai-launches-neuroterminal-platform-to-accelerate-neurological-clinical-trial-recruitment 2026-05-20T08:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-launches-pivotal-phase-2-3-revival-trial-of-pivekimab-sunirine-in-first-line-aml-expands-into-pediatric-setting 2026-05-20T08:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-launches-pivotal-phase-2-3-revival-trial-of-pivekimab-sunirine-in-first-line-aml-expands-into-pediatric-setting 2026-05-20T08:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/hephaistos-pharma-appoints-stephan-braun-as-chief-medical-officer-to-advance-tlr4-agonist-hepha440-toward-clinical-trials 2026-05-20T08:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hephaistos-pharma-appoints-stephan-braun-as-chief-medical-officer-to-advance-tlr4-agonist-hepha440-toward-clinical-trials 2026-05-20T08:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-novel-flt3xcd3-t-cell-engager-cln-049-in-relapsed-refractory-aml 2026-05-20T08:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-novel-flt3xcd3-t-cell-engager-cln-049-in-relapsed-refractory-aml 2026-05-20T08:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-seismiq-4ce-coronary-lithotripsy-catheter-meets-primary-endpoints-in-pivotal-fracture-trial 2026-05-20T08:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-seismiq-4ce-coronary-lithotripsy-catheter-meets-primary-endpoints-in-pivotal-fracture-trial 2026-05-20T08:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-experimental-alpha-1-antitrypsin-therapy-outperforms-standard-care-in-phase-3-trial 2026-05-20T08:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-experimental-alpha-1-antitrypsin-therapy-outperforms-standard-care-in-phase-3-trial 2026-05-20T08:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-faces-885-million-antitrust-verdict-for-delaying-generic-constipation-drug-amitiza 2026-05-20T07:57:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-faces-885-million-antitrust-verdict-for-delaying-generic-constipation-drug-amitiza 2026-05-20T07:57:10+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-demonstrates-superior-efficacy-over-standard-care-in-alpha-1-antitrypsin-deficiency-phase-2-trial 2026-05-20T07:55:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-efdoralprin-alfa-demonstrates-superior-efficacy-over-standard-care-in-alpha-1-antitrypsin-deficiency-phase-2-trial 2026-05-20T07:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-96-week-data-from-phase-2-solstice-trial-for-chronic-hepatitis-delta-at-easl-congress-2026 2026-05-20T07:53:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-96-week-data-from-phase-2-solstice-trial-for-chronic-hepatitis-delta-at-easl-congress-2026 2026-05-20T07:53:35+00:00 hourly 0.9 https://trial.medpath.com/news/ms-pharma-secures-strategic-investment-from-olayan-financing-company-to-accelerate-mena-biosimilars-expansion 2026-05-20T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ms-pharma-secures-strategic-investment-from-olayan-financing-company-to-accelerate-mena-biosimilars-expansion 2026-05-20T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/mesenchymal-stem-cell-therapy-shows-promise-for-rare-butterfly-skin-disease-in-spanish-clinical-trial 2026-05-20T07:47:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesenchymal-stem-cell-therapy-shows-promise-for-rare-butterfly-skin-disease-in-spanish-clinical-trial 2026-05-20T07:47:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-tezepelumab-efficacy-in-underrepresented-severe-asthma-populations 2026-05-20T07:45:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-tezepelumab-efficacy-in-underrepresented-severe-asthma-populations 2026-05-20T07:45:07+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-un-backed-group-to-expand-global-access-to-influenza-drug-xofluza 2026-05-20T07:42:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-un-backed-group-to-expand-global-access-to-influenza-drug-xofluza 2026-05-20T07:42:01+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-reports-positive-phase-2a-results-for-lam-001-in-pulmonary-hypertension 2026-05-20T07:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-reports-positive-phase-2a-results-for-lam-001-in-pulmonary-hypertension 2026-05-20T07:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/mavodelpar-shows-promise-in-phase-1-trial-for-primary-mitochondrial-myopathy 2026-05-20T07:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mavodelpar-shows-promise-in-phase-1-trial-for-primary-mitochondrial-myopathy 2026-05-20T07:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/12-year-old-becomes-first-indiana-patient-to-receive-fda-approved-gene-therapy-for-beta-thalassemia 2026-05-20T07:37:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/12-year-old-becomes-first-indiana-patient-to-receive-fda-approved-gene-therapy-for-beta-thalassemia 2026-05-20T07:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/hedge-fund-adar1-capital-invests-37-million-in-crinetics-pharmaceuticals-following-palsonify-launch 2026-05-20T07:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hedge-fund-adar1-capital-invests-37-million-in-crinetics-pharmaceuticals-following-palsonify-launch 2026-05-20T07:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-for-ai-driven-antibody-discovery 2026-05-20T07:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-for-ai-driven-antibody-discovery 2026-05-20T07:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/illuminare-biotechnologies-advances-nerve-visualization-drug-illuminare-1-to-phase-ii-trial-following-successful-phase-i-results 2026-05-20T07:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illuminare-biotechnologies-advances-nerve-visualization-drug-illuminare-1-to-phase-ii-trial-following-successful-phase-i-results 2026-05-20T07:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-s-vueject-receives-fda-510-k-clearance-and-health-canada-authorization-as-first-dedicated-ultrasound-contrast-delivery-system-for-cardiology-imaging 2026-05-20T07:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-s-vueject-receives-fda-510-k-clearance-and-health-canada-authorization-as-first-dedicated-ultrasound-contrast-delivery-system-for-cardiology-imaging 2026-05-20T07:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-invests-1-5-billion-in-mirus-for-revolutionary-nickel-free-tavr-technology 2026-05-20T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-invests-1-5-billion-in-mirus-for-revolutionary-nickel-free-tavr-technology 2026-05-20T07:32:47+00:00 hourly 0.9